DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 07/03/2020 -- Pemphigus Vulgaris Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Pemphigus Vulgaris Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total diagnosed Pemphigus Vulgaris prevalent cases in 7MM was 41,217 in 2017.
2. The diagnosed prevalent cases of Pemphigus Vulgaris was 5,275 cases in males and 8,251 cases in females in the US in 2017.

Key benefits of the report
1. Pemphigus Vulgaris market report covers a descriptive overview and comprehensive insight of the Pemphigus Vulgaris epidemiology and Pemphigus Vulgaris market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Pemphigus Vulgaris market report provides insights into the current and emerging therapies.
3. Pemphigus Vulgaris market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Pemphigus Vulgaris market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Pemphigus Vulgaris market.

Request for sample pages
"Pemphigus Vulgaris market size in 7MM was USD 181.78 million in 2017."

Pemphigus Vulgaris is an autoimmune disorder, on the skin, they are flaccid bullae or erosions, and on the mucosa, they present as erosions. The disease also is related—perhaps genetically—to other autoimmune conditions. Pemphigus Vulgaris Treatment is painful.

The US FDA approved Rituxan (rituximab) for the Pemphigus Vulgaris treatment of adults with moderate to severe Pemphigus Vulgaris in July 2018. The most recent guidelines by the international panel of experts recommend rituximab as a first-line treatment option for pemphigus. Rituxan is approved as MabThera in the EU.

The launch of the emerging therapies is expected to significantly impact Pemphigus Vulgaris treatment scenario in the upcoming years:-
Drugs covered
1. Rilzabrutinib (PRN1008)
2. Ianalumab (VAY736)
3. Efgartigimod (ARGX-113)
4. TPM203
And many others

The key players in Pemphigus Vulgaris market are:
1. Principia Biopharma
2. Novartis Pharmaceuticals/MorphoSys
3. Argenx BVBA
4. Topas Therapeutics
And many others

Table of contents
1 Key Insights
2 Executive Summary of Pemphigus Vulgaris (PV)
3 Pemphigus Vulgaris Market Overview at a Glance
4 Disease Background and Overview: Pemphigus Vulgaris (PV)
5 Case Reports
6 Pemphigus Vulgaris Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
8.1 Germany Epidemiology
8.2 France Epidemiology
8.3 Italy Epidemiology
8.4 Spain Epidemiology
8.5 United Kingdom Epidemiology
9 Japan Epidemiology
10 Current Pemphigus Vulgaris Treatment and Medical Practices
11 Unmet needs
12 Pemphigus Vulgaris Marketed Drugs
12.1 Mabthera/Rituxan: Genentech/Roche Group
13 Pemphigus Vulgaris Emerging Drugs
13.1 Key Cross Competition
13.2 Rilzabrutinib (PRN1008): Principia Biopharma
13.3 Ianalumab (VAY736): Novartis Pharmaceuticals/MorphoSys
13.4 Efgartigimod (ARGX-113): Argenx BVBA
13.5 TPM203: Topas Therapeutics
14 Pemphigus Vulgaris 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
16.1 Germany Market Size
16.2 France Market Size
16.3 Italy Market Size
16.4 Spain Market Size
16.5 United Kingdom Market Size
17 Japan Market Outlook
18 Pemphigus Vulgaris Market Drivers
19 Pemphigus Vulgaris Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 07/02/2020 -- Cytokine Release Syndrome Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Cytokine Release Syndrome Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. A total number of patients who develop Cytokine Release Syndrome following CART therapies in the 7MM was 31 in 2017.
2. A total number of Hematologic patients receiving CART-therapies in the 7MM was 41 in 2017.
3. Cytokine Release Syndrome cases in the United States was 31 in 2017.

Key benefits of the report
1. Cytokine Release Syndrome market report covers a descriptive overview and comprehensive insight of the Cytokine Release Syndrome epidemiology and Cytokine Release Syndrome market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Cytokine Release Syndrome market report provides insights into the current and emerging therapies.
3. Cytokine Release Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Cytokine Release Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cytokine Release Syndrome market.

Request for sample pages

"Cytokine Release Syndrome market size in the 7MM was USD 0.16 million in 2017."

Cytokine Release Syndrome is among the most frequent serious adverse events and represents a significant cause of morbidity following T-cell-engaging immunotherapy. The mechanisms of Cytokine Release Syndrome and the clinical use of corticosteroids and IL-6 blockade have already improved the management of Cytokine Release Syndrome patients.

Currently, there are many other IL-6-targeting monoclonal antibodies in late-stage clinical development, which could also potentially be used for Cytokine Release Syndrome treatment.

With the growing use of T-cell engaging therapies, there is an urgent need for clinical trials that improve the evidence base for the Cytokine Release Syndrome treatment. Our current management strategies for the disease are predominantly based on biologic reasoning, expert opinion, and retrospective analyses.

The recent approval of CAR T-cell therapies and their increase in the treatment of various oncology indications is increasing the Cytokine Release Syndrome incidence. The rise in the Cytokine Release Syndrome incidence stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products to be profitable. Companies across the globe have shifted their focus toward the treatment of Cytokine Release Syndrome. The increase in the incidence will potentiate the Cytokine Release Syndrome treatment market.

The launch of the emerging therapies is expected to significantly impact Cytokine Release Syndrome treatment scenario in the upcoming years:-
Drugs covered
1. Canakinumab (Ilaris)
2. Itacitinib
3. Cytosorb
4. Defitelio (Defibrotide)
5. Anakinra
And many others

The key players in Cytokine Release Syndrome market are:
1. Novartis Pharmaceuticals
2. Incyte Corporation
3. CytoSorbents
4. Jazz pharmaceuticals
5. Swedish Orphan Biovitrum (Sobi)
And many others

Table of contents
1Key Insights
2 Executive Summary of Cytokine Release Syndrome
3 Cytokine Release Syndrome Market Overview at a Glance
4 Disease Background and Overview Cytokine Release Syndrome
5 Case Reports
6 Cytokine Release Syndrome Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
8.1 Assumptions and Rationale
8.2 Germany Epidemiology
8.3 France Epidemiology
8.4 Italy Epidemiology
8.5 Spain Epidemiology
8.6 United Kingdom Epidemiology
9 Japan Epidemiology
10 Current Cytokine Release Syndrome Treatment and Medical Practices
11 Unmet needs
12 Cytokine Release Syndrome Marketed Drugs
12.1 Actemra/RoActemra (tocilizumab): Genentech
13 Cytokine Release Syndrome Emerging Drugs
13.1 Key Cross Competition
13.2 Canakinumab (Ilaris): Novartis Pharmaceuticals
13.3 Itacitinib: Incyte Corporation
13.4 Cytosorb: CytoSorbents
13.5 Defitelio (Defibrotide): Jazz pharmaceuticals
13.6 Anakinra: Swedish Orphan Biovitrum (Sobi)
14 Cytokine Release Syndrome 7MM Market Analysis
15 Conjoint Analysis
16 United States
16.1 United States Market Outlook
16.2 United States Market Size
17 EU-5 Countries: Market Outlook
17.1 Germany Market Size
17.2 France Market Size
17.3 Italy Market Size
17.4 Spain Market Size
17.5 United Kingdom Market Size
18 Japan Market Outlook
19 Cytokine Release Syndrome Market Drivers
20 Cytokine Release Syndrome Market Barriers
21 SWOT Analysis
22 Reimbursement and market access
23 Appendix
24 DelveInsight Capabilities
25 Disclaimer
26 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 07/01/2020 -- Acute Lymphocytic Leukemia Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Acute Lymphocytic Leukemia Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
- The total Acute Lymphocytic Leukemia incident cases was 10,341 in the 7MM in 2017.
- Acute Lymphocytic Leukemia is more frequent in males compared to females.
- The total Acute Lymphocytic Leukemia incident cases in the United States was 5,816 in 2017.

Key benefits of the report
1. Acute Lymphocytic Leukemia market report covers a descriptive overview and comprehensive insight of the Acute Lymphocytic Leukemia epidemiology and Acute Lymphocytic Leukemia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Acute Lymphocytic Leukemia market report provides insights into the current and emerging therapies.
3. Acute Lymphocytic Leukemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Acute Lymphocytic Leukemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Lymphocytic Leukemia market.

Request for sample pages

"Acute Lymphocytic Leukemia market size in the 7MM was USD 1,246 million in 2017."

Chemotherapy is often complicated and intense, particularly in the initial months of Acute Lymphocytic Leukemia Treatment. The most common treatment regimens use a combination of more than one anticancer drug. Induction is the first phase of chemotherapy, and the goal of this phase is to induce a remission.

In this phase, numerous drugs are usually being used depending on the patient's age, the specific features of leukaemia, and the overall health of the patient. Induction regimens for Acute Lymphocytic Leukemia generally use a combination of drugs that include vincristine; anthracyclines (daunorubicin, doxorubicin); and corticosteroids (prednisone, dexamethasone) administered either with or without asparaginase and cyclophosphamide.

For Acute Lymphocytic Leukemia treatment landscape of ALL, protein kinase inhibitors have also offered hope as new drugs for acute leukaemia treatment. In 2013, the US FDA approved Gleevec (Imatinib; Novartis Pharmaceuticals) to treat children newly diagnosed Ph+ ALL. In the EU, Glivec is also approved for the treatment of adult patients with newly diagnosed Ph+ ALL in combination with chemotherapy and as a single agent for patients with relapsed or refractory Ph+ ALL.

The launch of the emerging therapies is expected to significantly impact Acute Lymphocytic Leukemia treatment scenario in the upcoming years:-
Acute lymphocytic leukemia Pipeline Therapies
1. Imbruvica (Ibrutinib): Pharmacyclics (an AbbVie Company)
2. Jakafi (ruxolitinib): Incyte Corporation/Novartis
3. Motixafortide (BL-8040): BioLine Rx
4. TC-110: TCR2 Therapeutics
5. Lisocabtagene Maraleucel (JCAR017): Bristol-Myers Squibb
6. TBI-1501: Takara Bio/Otsuka Pharmaceuticals
7. UCART19: Servier/Allogene
8. Venetoclax: AbbVie and Roche
9. NiCord (omidubicel): Gamida Cell Ltd.
10. Eliquis (apixaban): Bristol-Myers Squibb|Pfizer
11. Isatuximab: Sanofi
12. JZP-458 (recombinant Erwinia asparaginase): Jazz Pharmaceuticals
13. Vyxeos (Daunorubicin and Cytarabine for Injection): Jazz Pharmaceuticals
14. Daratumumab: Janssen Research & Development
15. ProTmune: Fate Therapeutics
16. MB-CART19.1: MiltenyiBiotec B.V. & Co. KG
17. BPX-501 T Cells (rivogenlecleucel; iC9-CAR19 cells): Bellicum Pharmaceuticals
18. PBCAR0191: Precision BioSciences/Servier
19. AUTO1: Autolus Limited
20. KTE-X19: Gilead Sciences
And many others

Table of contents
1. Key Insights
2. Executive Summary of Acute lymphocytic leukemia
3. SWOT Analysis of Acute lymphocytic leukemia
4. Acute lymphocytic leukemia Market Overview at a Glance
5. Acute lymphocytic leukemia: Disease Background and Overview
6. Acute lymphocytic leukemia Diagnosis
7. Acute lymphocytic leukemia Epidemiology and Patient Population
8. The United States Acute lymphocytic leukemia Epidemiology
9. EU-5 Country-wise Acute lymphocytic leukemia Epidemiology
10. Japan Acute lymphocytic leukemia Epidemiology
11. Current Acute lymphocytic leukemia Treatment Practices
12. Acute lymphocytic leukemia Treatment Algorithms
13. Acute lymphocytic leukemia Guideline
14. Unmet Needs in Acute lymphocytic leukemia Market
15. Acute lymphocytic leukemia: Patient Journey
16. Key Endpoints in Acute lymphocytic leukemia Clinical Trials
17. Acute lymphocytic leukemia Marketed Therapies
18. Emerging Acute lymphocytic leukemia Therapies
19. Conjoint Analysis of Acute lymphocytic leukemia
20. Acute lymphocytic leukemia: Seven Major Market Analysis
21. 7MM Acute lymphocytic leukemia Market Size
22. United States Acute lymphocytic leukemia Market Size
23. EU-5 Acute lymphocytic leukemia Market Size
24. Japan Acute lymphocytic leukemia Market Size
25. Market Access and Reimbursement of Acute lymphocytic leukemia Therapies
26. Acute lymphocytic leukemia Market Drivers
27. Acute lymphocytic leukemia Market Barriers
28. Appendix
29. DelveInsight Capabilities
30. Disclaimer
31. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 06/30/2020 -- CDKL5 Deficiency Disorder Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on CDKL5 Deficiency Disorder Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
- The total prevalent population of CDKL5 Deficiency Disorder in 7MM was 16,397 in 2017.
- The total diagnosed CDKL5 Deficiency Disorder prevalence in the United States was 208 cases of males and 1,315 cases of females in 2017.

Key benefits of the report
1. CDKL5 Deficiency Disorder market report covers a descriptive overview and comprehensive insight of the CDKL5 Deficiency Disorder epidemiology and CDKL5 Deficiency Disorder market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. CDKL5 Deficiency Disorder market report provides insights into the current and emerging therapies.
3. CDKL5 Deficiency Disorder market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. CDKL5 Deficiency Disorder market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the CDKL5 Deficiency Disorder market.

Request for sample pages

"CDKL5 Deficiency Disorder market size in 7MM was USD 5.95 Million in 2017."

Currently, there are no approved therapies for CDKL5 Deficiency Disorder. The treatment landscape of CDKL5 Deficiency Disorder includes multidisciplinary care, including anti-epileptic drugs, anticonvulsants, physiotherapy, occupational therapy, neurological speech therapy, and dietetics.

One of the most common features of CDKL5 Deficiency Disorder is seizures that are typically challenging and are often the most challenging health issue to manage. No one anticonvulsant is uniformly effective, and often multiple anticonvulsants are needed. If seizures are refractory, then other treatments such as steroids and Intravenous Immunoglobulin (IVIG) are suggested. If medications are not sufficient, other treatment options include Implantation of a Vagus Nerve Stimulator (VNS) and Corpus Callosotomy.

The launch of the emerging therapies is expected to significantly impact CDKL5 Deficiency Disorder treatment scenario in the upcoming years:-
Drugs covered
1. Ganaxolone
2. Soticlestat (TAK935/OV935)
3. Fintepla (ZX008)
4. Translarna (ataluren)
And many others

The key players in CDKL5 Deficiency Disorder market are:
1. Marinus Pharmaceuticals
2. Takeda
3. Ovid Therapeutics
4. Zogenix
5. PTC Therapeutics
And many others

Table of contents
1 Key Insights
2 Executive Summary
3 SWOT Analysis
4 CDKL5 Deficiency Disorder Market Share Distribution in 2030
5 Disease Background and Overview - CDKL5 Deficiency Disorder
6 Recognized Establishments
7 CDKL5 Deficiency Disorder Treatment
8 CDKL5 Deficiency Disorder Epidemiology and Patient Population
9 Total Prevalent Population of CDKL5 Deficiency Disorder in the 7MM
10 Total Diagnosed Prevalent Population of CDKL5 Deficiency Disorder in the 7MM
11 Epidemiology of CDLK5 Deficiency Disorder in the 7MM
11.1 United States
11.2 Germany
11.3 France
11.4 Italy
11.5 Spain
11.6 United Kingdom
11.7 Japan
12 Unmet Needs
13 CDKL5 Deficiency Disorder Emerging Drugs
13.1 Key Cross Competition
13.2 Ganaxolone: Marinus Pharmaceuticals
13.3 Soticlestat (TAK935/OV935): Takeda/Ovid Therapeutics
13.4 Fintepla (ZX008): Zogenix
13.5 Translarna (ataluren): PTC Therapeutics
14 Attribute Analysis
15 Key CDKL5 Deficiency Disorder Market Assumptions
16 CDKL5 Deficiency Disorder Market Access and Reimbursement
17 CDKL5 Deficiency Disorder Seven Major Market Analysis
18 Case Reports
19 CDKL5 Deficiency Disorder Market Drivers
20 CDKL5 Deficiency Disorder Market Barriers
21 Appendix
22 CDKL5 Deficiency Disorder Report Methodology
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 06/29/2020 -- Hereditary Angioedema Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Hereditary Angioedema Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. Hereditary Angioedema affects one in 50,000 individuals in the United States.
2. Hereditary Angioedema prevalence in Japan is estimated to be 4.1 per 10 million people.
3. Hereditary Angioedema is more prevalent among females than males.

Key benefits of the report
1. Hereditary Angioedema market report covers a descriptive overview and comprehensive insight of the Hereditary Angioedema epidemiology and Hereditary Angioedema market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Hereditary Angioedema market report provides insights into the current and emerging therapies.
3. Hereditary Angioedema market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Hereditary Angioedema market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hereditary Angioedema market.

Request for sample pages

Hereditary Angioedema is a rare, potentially life-threatening inherited disorder with symptoms of severe, painful, and recurring attacks of oedema (swelling). Hereditary Angioedema patients often suffer for many years and may be subject to unnecessary medical procedures and surgery before receiving an accurate diagnosis. Therapy for Hereditary Angioedema can be generally divided into two approaches, acute (or on-demand) treatment of attacks and prevention of attacks, which is broken down into short-term prophylaxis (STP) and long-term prophylaxis (LTP).

In the current treatment landscape for on-demand Hereditary Angioedema treatment, there are several options, such as intravenous plasma-derived C1-INH (C1-INH[IV]), recombinant human C1-INH, icatibant (a bradykinin B2-receptor antagonist), and ecallantide (a kallikrein inhibitor). However, current prophylactic treatment approaches are minimal and have major tolerability issues due to challenging administration requirements leaving patients with few therapeutic options.

Hereditary Angioedema treatment options in the United States were severely lacking or associated with significant adverse effects; however, few products are currently approved and registered by the FDA, the EMA and many other countries to treat Hereditary Angioedema with additional agents currently undergoing clinical trials.

In 2017, the pdC1-INH agent (Haegarda) was approved by the FDA for prophylaxis of HAE in adolescent and adult patients. This is the second agent approved for Hereditary Angioedema prophylaxis and the first C1-INH for SC administration. In 2009, the FDA approved Berinert, to treat acute abdominal attacks and facial swelling associated with Hereditary Angioedema in adults and adolescents. Then in 2016, FDA approved Berinert, as the first and only pediatric treatment for Hereditary Angioedema.

The launch of the emerging therapies is expected to significantly impact Hereditary Angioedema treatment scenario in the upcoming years:-

Drugs covered
1. BCX7353
2. IONIS-PKK-LRx
3. ATN-249
And many others

The key players in Hereditary Angioedema market are:
1. BioCryst Pharmaceuticals
2. Ionis Pharmaceuticals
3. Attune Pharma
And many others

Table of contents
1. Report Introduction
2. Hereditary Angioedema Market Overview at a Glance
3. Disease Background and Overview: Hereditary Angioedema
4. Hereditary Angioedema Epidemiology and Patient Population
5. Hereditary Angioedema Country-Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Japan
6. Hereditary Angioedema Treatments & Medical Practices
7. Hereditary Angioedema Marketed Therapies
7.1. Key Cross Competition
7.2. Berinert: CSL Behring
7.3. Takhzyro: Takeda
8. Hereditary Angioedema Emerging Therapies
8.1. Key Cross Competition
8.2. BCX7353: BioCryst Pharmaceuticals
8.3. IONIS-PKK-LRx: Ionis Pharmaceuticals
8.4. ATN-249: Attune Pharma
9. Hereditary Angioedema Market Size
9.1. Key Findings
9.2. Total 7MM Hereditary Angioedema Market Analysis
10. 7MM: Country-Wise Market Analysis
10.1. United States Market Size
10.2. EU-5
10.2.1. Germany Market Size
10.2.2. France Market Size
10.2.3. Italy Market Size
10.2.4. Spain Market Size
10.2.5. United Kingdom Market Size
10.3. Japan Market Size
11. Hereditary Angioedema Market Drivers
12. Hereditary Angioedema Market Barriers
13. Appendix
14. Hereditary Angioedema Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 06/26/2020 -- Systemic Sclerosis Market Insights, Epidemiology and Market Forecast-2030

(Albany, US)DelveInsight launched a new report on Systemic Sclerosis Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report

1. Systemic Sclerosis is a rare disease and is diagnosed in approximately 67 male patients and 265 female patients, per 100,000 people each year in the United States.
2. Systemic Sclerosis usually appears in women aged 30–40, and it occurs in slightly older men. In approximately 85% of cases, systemic sclerosis develops in individuals aged 20–60 years.
3. The female population is more prone to Systemic Sclerosis as compared to the male population.

Key benefits of the report

1. Systemic Sclerosis market report covers a descriptive overview and comprehensive insight of the Systemic Sclerosis epidemiology and Systemic Sclerosis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Systemic Sclerosis market report provides insights into the current and emerging therapies.
3. Systemic Sclerosis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Systemic Sclerosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Systemic Sclerosis market.

Request for sample pages

No treatment has been proven to modify the overall disease course, but the therapy targets specific organ involvement early before irreversible damage to improve both qualities of life and survival. The therapeutic Systemic Sclerosis market is driven by the increase in prevalent cases and is mainly driven by the patient pools of 30–50 years. The therapeutic Systemic Sclerosis market size is accounted for therapies directed toward the management of specific symptoms, and current therapies use medications that aim the four main features of the disease that is inflammation, autoimmunity, vascular disease, and tissue fibrosis.

Currently, immunosuppressive agents such as methotrexate, Cyclophosphamide, mycophenolate mofetil, Azathioprine; autologous stem cell transplantation, and others are therapeutic choices for Systemic Sclerosis.

Treatment of Systemic Sclerosis varies according to the manifestation such as cutaneous, pulmonary, gastric, heart, and renal, and most of the therapies aim to treat the specific organ involvement to avoid irreversible damage as well as to improve both qualities of life and survival.

Cutaneous and pulmonary manifestations are the significant expositions of Systemic Sclerosis, and Intravenous Cyclophosphamide, Methotrexate, Mycophenolate Mofetil (MMF), or Azathioprine are recommended for the treatment. Besides, Cyclophosphamide is prescribed for improving the skin changes among patients with Systemic Sclerosis associated with interstitial lung disease.

The launch of the emerging therapies is expected to significantly impact Systemic Sclerosis treatment scenario in the upcoming years:-
Drugs covered
1. Lenabasum
2. Brodalumab
And many others

The key players in Systemic Sclerosis market are:
1. Corbus Pharmaceuticals
2. Kyowa Hakko Kirin
And many others

Table of contents
1. Systemic Sclerosis Report Introduction

2. Systemic Sclerosis Market Overview at a Glance

3. Systemic Sclerosis Disease Background and Overview

4. Systemic Sclerosis Epidemiology and Patient Population

5. Systemic Sclerosis Country-Wise Epidemiology

6. United States

6.1. Prevalent Cases of Systemic Sclerosis (SSc) in the United States (2017–2030)

6.3. Gender-specific Cases of Systemic Sclerosis (SSc) in the United States (2017–2030)

6.4. Type-specific Cases of Systemic Sclerosis (SSc) in the United States (2017–2030)

6.5. Prevalent cases of SSc based on Clinical Manifestations in the United States (2017–2030)

6.6. EU–5

6.6.1. Assumptions and Rationale

6.6.2. Germany

6.6.3. France

6.6.4. Italy

6.6.5. Spain

6.6.6. United Kingdom

6.7. Japan

7. Systemic Sclerosis Treatments & Medical Practices

8. Systemic Sclerosis Emerging Therapies

9. Key Cross Competition

9.1. Lenabasum: Corbus Pharmaceuticals

9.2. Brodalumab: Kyowa Hakko Kirin

10. Systemic Sclerosis Market Size

11. 7MM Systemic Sclerosis Country-Wise Market Analysis

12. United States Market Size

13. EU5 Market Size

13.1. Germany Market Size

13.2. France Market Size

13.3. United Kingdom Market Size

13.4. Spain Market Size

13.5. Italy Market Size

14. Japan Market Size

15. Systemic Sclerosis Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 06/25/2020 -- Lambert-Eaton Myasthenic Syndrome (LEMS) Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Lambert-Eaton Myasthenic Syndrome (LEMS) Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
- The total prevalent population of LEMS in the 7MM was 5,977 in 2017.
- The prevalence of LEMS in the United States was 3,255
- Males are more affected by the disease as compared to females in the US in 2017 with 1,258 cases in males, whereas 720 cases for females.

Key benefits of the report
1. Lambert-Eaton Myasthenic Syndrome market report covers a descriptive overview and comprehensive insight of the LEMS epidemiology and LEMS market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. LEMS market report provides insights into the current and emerging therapies.
3. Lambert-Eaton Myasthenic Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Lambert-Eaton Myasthenic Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the LEMS market.

Request for sample pages

"LEMS therapeutic market in 7MM was USD 59.43 million in 2017."

Currently, there is no cure for the disease LEMS treatment is mainly symptomatic. This includes 3, 4-diaminopyridine phosphate (DAP), which is usually well-tolerated and effective. In some patients, the combination of pyridostigmine with 3, 4-DAP has been suggested to have an additional positive effect. If symptomatic treatment is insufficient, immunosuppressive therapy with prednisone, alone or in combination with azathioprine, can achieve long-term control of the disorder.

Plasmapheresis and high dose administration of intravenous immunoglobulins (IVIGs) have a short effect. An effective treatment against any tumour present is mandatory, both to control the tumour and to improve the clinical symptoms of LEMS.

One-half of the patients suffering from LEMS have an idiopathic form, the other half a tumour-associated form of the disease. In general, LEMS responds well to symptomatic and immunosuppressive treatments.
So far, there are only two FDA approved the medication for LEMS, i.e., Firdapse and Ruzurgi. The FDA's approval of Firdapse is a potentially transformative milestone in the lives of patients in the US suffering from LEMS, as it now gives adult LEMS patients access to a new first-in-class-therapy.

Firdapse is approved in the US and the European Union for patients with LEMS. After the approval of Firdapse, Ruzurgi is the second drug to be approved in the US for the treatment of LEMS and first approved the medication for the Lambert-Eaton Myasthenic Syndrome treatment in patients six years to less than 17 years of age. Despite being a potential therapy in the treatment, a lawsuit has been filed by Catalyst Pharma against the US FDA and several related parties challenging the recent approval of an NDA and related drug labelling for Ruzurgi for the treatment of LEMS in pediatric patients.

Drugs covered in the report:-
Marketed Drugs
1. Ruzurgi
2. Firdapse
And many others

The key players in LEMS market are:
1. Jacobus Pharmaceutical
2. Catalyst Pharmaceutical
And many others

Table of contents

1. Key Insights

2. Executive Summary

3. Lambert–Eaton Myasthenic Syndrome Market Overview at a Glance (Base Case Scenario)

4. LEMS Market Overview at a Glance (Downside Scenario)

5. Lambert–Eaton Myasthenic Syndrome Disease Overview

6. Case Reports

7. Lambert–Eaton Myasthenic Syndrome Epidemiology and Patient Population

8. United States Epidemiology

9. EU-5 Lambert–Eaton Myasthenic Syndrome Epidemiology

9.1. Germany

9.2. France

9.3. Italy

9.4. Spain

9.5. United Kingdom

10. Japan Epidemiology

11. Lambert–Eaton Myasthenic Syndrome Treatment

12. Unmet Needs

13. Lambert–Eaton Myasthenic Syndrome Marketed Drugs

13.1. Firdapse: Catalyst Pharmaceutical

13.2. Ruzurgi: Jacobus Pharmaceutical

14. Lambert–Eaton Myasthenic Syndrome 7MM Market Analysis

15. LEMS Market Outlook: The United States

16. LEMS Market Outlook: Europe

16.1. Germany

16.2. France

16.3. Italy

16.4. Spain

16.5. United Kingdom

17. Market Outlook: Japan

18. LEMS Market Drivers

19. LEMS Market Barriers

20. SWOT Analysis

21. KOL Views

22. Reimbursement and market access

23. Appendix

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 06/24/2020 -- Rosacea Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Rosacea Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total prevalent population of Rosacea in the 7MM was 47,634,256 in 2017.
2. The prevalence of Rosacea was found in the United States with 16,652,170 cases in 2017.
3. Germany had a prevalent population of Rosacea with 8,383,943 cases in 2017.
4. France had Rosacea prevalent population of 6,082,002 cases in 2017.
5. Italy had a prevalent population of Rosacea with 3,217,083 cases in 2017.

Key benefits of the report
1. Rosacea market report covers a descriptive overview and comprehensive insight of the Rosacea epidemiology and Rosacea market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Rosacea market report provides insights into the current and emerging therapies.
3. Rosacea market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Rosacea market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Rosacea market.

Request for sample pages

"Rosacea prevalence is high in females than in males".

The current Rosacea therapeutic landscape can be divided into four major categories based on the route of administration and the approved usage for the condition. These are topical retinoids, topical antibiotics, oral tetracycline-class antibiotics (TCAs), and oral retinoids.

Among Topical therapies, topical retinoids mainly include Tretinoin, Tazarotene, Adapalene, and Clindamycin/tretinoin, and several others are used to reduce erythema, papules and pustules, and telangiectasias. Among these, Tretinoin has the lowest cost and most commonly prescribed topical retinoid, accounting for the majority of the population.

Topical antibiotics, such as metronidazole (e.g. Metrolotion), clindamycin, erythromycin, azelaic acid (e.g. Fincea), benzoyl peroxide, benzoyl peroxide/clindamycin, benzoyl peroxide/erythromycin, sulfacetamide, and sulfacetamide/sulfur, are applied directly to the skin to kill bacteria on the surface of the skin.

Topical antibiotics are the most commonly prescribed class of drug for all sexes and age groups. The most common topical antibiotics prescribed are metronidazole (for an estimated half of the population of topical antibiotics) followed by clindamycin, erythromycin, and azelaic acid.

The launch of the emerging therapies is expected to significantly impact Rosacea treatment scenario in the upcoming years:-
Drugs covered
- FMX103
- Epsolay
- ACU-D1
- HY01
- AFX-4031
- AOB103
And many others

The key players in the Rosacea market are:
- Foamix Pharmaceuticals
- Sol-Gel
- Accuitis
- Hovione Scientia Limited
- Afecta Pharmaceuticals
- AOBiome
And many others

Table of contents
1. Key Insights
2 Executive Summary of Rosacea
3. Rosacea Market Overview at a Glance
4. Rosacea Disease Background and Overview: Rosacea
5. Rosacea Epidemiology and Patient Population
6. Country Wise-Epidemiology of Rosacea Disease
6.1. United States
6.2. EU5 Countries
6.2.1. Germany
6.2.2. France
6.2.3. Italy
6.2.4. Spain
6.2.5. United Kingdom
6.3. Japan
7. Rosacea Treatment Algorithm, Current Treatment, and Medical Practices
8. Unmet Needs
9. Rosacea Marketed Drugs
9.1. Rhofade: Allergan
9.2. Oracea: Galderma Laboratories (Nestle Skin Health)
9.3. Mirvaso: Galderma Laboratories (Nestle Skin Health)
9.4. Finacea: Bayer
9.5. Soolantra: Galderma Laboratories, Inc. (Nestle Skin Health)
9.6. Metrogel: Galderma Laboratories (Nestle Skin Health)
10. Key Cross Competition
11. Rosacea Emerging Drugs
11.1. FMX103: Foamix Pharmaceuticals
11.2. Epsolay: Sol-Gel
11.3. ACU-D1: Accuitis
11.4. HY01: Hovione Scientia Limited
11.5. AFX-4031: Afecta Pharmaceuticals
11.6. AOB103: AOBiome
12. Rosacea 7 Major Market Analysis
13. The United States Market Outlook
14. EU-5 Countries: Market Outlook
14.1. Germany
14.2. France
14.3. Italy
14.4. Spain
14.5. United Kingdom
15. Japan: Market Outlook
16. Access and Reimbursement Overview of Rosacea
17. Rosacea Market Drivers
18. Rosacea Market Barriers
19. SWOT Analysis
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 06/22/2020 -- Postpartum Depression Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Postpartum Depression Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
- The total diagnosed prevalent population of Postpartum Depression in the 7MM in 2017 was 1,134,800.
- The diagnosed prevalent cases of Postpartum Depression in the United States was 609,900 in 2017.

Key benefits of the report
1. Postpartum Depression market report covers a descriptive overview and comprehensive insight of the Postpartum Depression epidemiology and Postpartum Depression market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Postpartum Depression market report provides insights into the current and emerging therapies.
3. Postpartum Depression market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Postpartum Depression market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Postpartum Depression market.

Request for sample pages
"Postpartum Depression market size in the 7MM was USD 138.75 Million in 2017".

Antidepressant medications, cognitive-behavioural therapy (CBT), and interpersonal therapy are useful in the Postpartum Depression (PPD) treatment.

There is only one FDA approved drug, namely, Zulresso- a neuroactive steroid gamma-aminobutyric acid (GABA), a receptor-positive modulator indicated for the treatment of postpartum depression (PPD) in adults.

Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate) and Paxil CR (paroxetine) form the mainstay drug Postpartum Depression treatment. Although these drugs are approved for treating depression-related disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), etc., they are being used as off-label drugs for the Postpartum Depression treatment.

Postpartum Depression can be treated using a combination of therapy and antidepressant medications. One such class of medication is known as selective serotonin reuptake inhibitors (SSRIs), which includes fluoxetine and sertraline. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) has also been found useful in the treatment of Postpartum Depression. SSRIs relieve symptoms by preventing the reabsorption, or reuptake, of serotonin by specific nerve cells in the brain; this increases the level of available serotonin, which improves the mood of the patient.

Drugs covered in the report:-
Emerging Therapies
. Zuranolone (SAGE-217): Sage Therapeutics
. Ganaxolone (CCD-1042): Marinus Pharmaceuticals
And many others

Marketed Drug
. Zulresso (brexanolone): Sage Therapeutics

And many others
Table of contents
1 Key Insights
2 Postpartum depression Market Overview at a Glance
3 Disease Background and Overview: Postpartum depression (PPD)
4 Postpartum Depression Epidemiology and Patient Population
5 Country-Wise Epidemiology of Postpartum Depression (PPD)
5.1 United States
5.2 EU5 Countries
5.3 Germany
5.4 France
5.5 Italy
5.6 Spain
5.7 United Kingdom
5.8 Japan
6 Postpartum Depression Treatment
7 Postpartum Depression Treatment Algorithm by American Family Physician (AFP)
8 Postpartum Depression Treatment Guidelines by Unicare
9 Postpartum Depression Treatment Guidelines by the National Institute for Health and Care Excellence (NICE)
10 Recognized Establishments
11 Unmet Needs
12 Postpartum Depression Marketed Profile
12.1 Zulresso (brexanolone): Sage Therapeutics
12.2 Postpartum Depression Emerging Drugs
12.3 Key Cross Competition
12.4 Zuranolone (SAGE-217): Sage Therapeutics
12.5 Ganaxolone (CCD-1042): Marinus Pharmaceuticals
13 Postpartum Depression: 7 Major Market Analysis
14 The United States Market Outlook
14.1 United States Market Size
14.1 Germany
14.2 France
14.3 Italy
14.4 Spain
14.5 United Kingdom
15 Japan: Market Outlook
16 KOL Reviews
17 Case Reports
18 Market Drivers
19 Market Barriers
20 SWOT Analysis
21 Appendix
22 DelveInsight Capabilities
23 Disclaimer
24 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 06/18/2020 -- Familial Hypercholesterolemia Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Familial Hypercholesterolemia Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total diagnosed prevalent population of Familial Hypercholesterolemia in the 7MM was 965,405 in 2017.
2. The diagnosed prevalent population of Familial Hypercholesterolemia in the United States was 244,214 in 2017.
3. The diagnosed prevalent population of Familial Hypercholesterolemia in Japan in 2017 was 221,519
4. Familial Hypercholesterolemia affects both females and males equally.
Key benefits of the report
1. Familial Hypercholesterolemia market report covers a descriptive overview and comprehensive insight of the Familial Hypercholesterolemia epidemiology and Familial Hypercholesterolemia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Familial Hypercholesterolemia market report provides insights into the current and emerging therapies.
3. Familial Hypercholesterolemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Familial Hypercholesterolemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Familial Hypercholesterolemia market.

Request for sample pages

"The market size of Familial Hypercholesterolemia in the 7MM in 2017- 1,069.27 USD Million."

Early diagnosis and Familial Hypercholesterolemia treatment are vital to reduce the risk of premature atherosclerotic cardiovascular disease and death. The goal of Familial Hypercholesterolemia treatment is to reduce LDL-C by 50 % from baseline levels with lifestyle modification, pharmacologic lipid-lowering therapy, and LDL apheresis and in rare cases, liver transplantation.

Statins are first-line pharmacologic therapy agents in the treatment of Familial Hypercholesterolemia as they reduce cardiovascular mortality even in receptor-negative patients. The FDA has approved many statins for the treatment of Familial Hypercholesterolemia, namely, Mevacor (lovastatin), Pravachol (pravastatin), and Zocor (simvastatin) which are fungal-derived statins, while Lipitor (atorvastatin), Lescol (fluvastatin), Livalo (pitavastatin), and Ezallortm (rosuvastatin) are synthetic compounds.

Mipomersen is a second-generation antisense oligonucleotide that targets the messenger ribonucleic acid (mRNA) that encodes ApoB-100 produced by the liver. It is marketed by the brand name Kynamro. It distributes mainly to the liver, where it forms a duplex with the target mRNA, causing the mRNA to be cleaved by RNase H and therefore unable to be translated to apoB-100. Hepatic Apo mRNA silencing gives rise to reductions in hepatic Apo and plasma total cholesterol, LDL-cholesterol, and Apo concentrations in a dose- and time-dependent manner.

The launch of the emerging therapies is expected to significantly impact Familial Hypercholesterolemia treatment scenario in the upcoming years:-
Drugs covered
1. Evinacumab (REGN1500)
2. Inclisiran (ALN-PCSSC)
3. LIB003 + Evolocumab
4. Gemcabene
5. Resmetirom (MGL-3196)
6. ARO-ANG3
And many others

The key players in Familial Hypercholesterolemia market are:
1. Regeneron Pharmaceuticals
2. Novartis
3. LIB Therapeutics
4. NeuroBo Pharmaceuticals
5. Madrigal Pharmaceuticals
6. Arrowhead Pharmaceuticals
And many others

Table of contents
1 Key Insights
2 Familial Hypercholesterolemia Market Overview at a Glance
3 Familial Hypercholesterolemia Disease Background and Overview
4 Diagnostic guidelines for Familial Hypercholesterolemia by the American Heart Association (AHA)
5 Diagnostic guidelines for Familial Hypercholesterolemia by the National Institute for Health and Care Excellence (NICE)
6 Recognized Establishments
7 Familial Hypercholesterolemia Epidemiology and Patient Population: Key Findings
8 Country Wise-Epidemiology of Familial Hypercholesterolemia
8.1 United States
8.2 EU5 Countries
8.3 Germany
8.4 France
8.5 Italy
8.6 Spain
8.7 United Kingdom
8.8 Japan
9 Familial Hypercholesterolemia Treatment
10 Familial Hypercholesterolemia Treatment guidelines by the American Heart Association (AHA)
11 Familial Hypercholesterolemia Treatment guidelines by the National Institute for Health and Care Excellence (NICE)
12 Treatment guidelines for Familial Hypercholestrolemia by the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Diseases
13 Unmet Needs
15 Familial Hypercholesterolemia Marketed Drugs
15.1 Marketed Drugs Key-cross Competition
15.2 Praluent (alirocumab): Sanofi/ Regeneron Pharmaceuticals
15.3 Repatha (evolocumab): Amgen
15.4 Nustendi (bempedoic acid / ezetimibe): Esperion Therapeutics
16 Familial Hypercholesterolemia Emerging Drugs
16.1 Key Cross Competition
16.2 Evinacumab (REGN1500): Regeneron Pharmaceuticals
16.3 Inclisiran (ALN-PCSSC): Novartis
16.4 LIB003 + Evolocumab: LIB Therapeutics
16.5 Gemcabene: NeuroBo Pharmaceuticals
16.6 Resmetirom (MGL-3196): Madrigal Pharmaceuticals
16.7 ARO-ANG3: Arrowhead Pharmaceuticals
17 Familial Hypercholesterolemia 7 Major Market Analysis
17.4 United States Market Size
17.5 Germany Market Size
17.6 France Market Size
17.7 Italy Market Size
17.8 Spain Market Size
17.9 United Kingdom Market Size
17.10 Japan market Size
18 Case Reports
19 Market Drivers
20 Market Barriers
21 SWOT Analysis for Familial Hypercholesterolemia
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 06/17/2020 -- Beta-thalassemia Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Beta-thalassemia Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total prevalent population of Beta-thalassemia in 6MM was 14,191 in 2017.
2. The total prevalent cases for Beta-thalassemia were highest in Italy, followed by the United States and Germany.
3. Endocrine complications and Osteoporosis was found in the majority of patients with Beta-Thalassemia.

Key benefits of the report
1. Beta-thalassemia market report covers a descriptive overview and comprehensive insight of the Beta-thalassemia epidemiology and Beta-thalassemia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Beta-thalassemia market report provides insights into the current and emerging therapies.
3. Beta-thalassemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Beta-thalassemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Beta-thalassemia market.

Request for sample pages

Beta Thalassemia is a genetic disorder which is inherited in an autosomal, recessive fashion. The clinical manifestations seen in patients are severe anaemia, abnormal haemoglobin and buildup of iron in the body. Being a genetic disorder, there is no specific treatment for Beta Thalassemia and the treatment regimen mainly focus on delaying progression of the disease and relieving the symptoms.

The main complication from frequent blood transfusions is iron overload, as the human body lacks a method of excreting excess iron. Iron accumulation, particularly in the heart, liver, and pituitary gland, can lead to heart failure, cirrhosis, hepatocellular carcinoma, hypothyroidism, hypoparathyroidism, hypogonadism, diabetes, and growth failure. Iron chelation therapy is the primary method of both treating and preventing iron overload. The primary goal of chelation is to maintain iron balance in the body by excreting excess iron through urine or faeces. Thus, owing to the symptomatic treatment in the target patient population, the current market of Beta Thalassemia covered in the report solely focuses on the market revenue generated by iron binders/chelators.
There are some iron chelators used in iron chelation therapies, namely: Deferoxamine (DFO), Deferiprone (DFP) and Deferasirox (DFX). These are either given alone or in combination, Desferal (deferoxamine mesylate USP), developed by Novartis.

Desferal is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anaemia. Desferal can promote iron excretion in patients with secondary iron overload from multiple transfusions—as may occur in the treatment of some chronic anaemias, including thalassemia. Besides, it can be given by intramuscular, subcutaneous, and intravenous routes of administration.

Novartis developed Exjade (Deferasirox), which is an oral iron chelator approved by the US FDA in 2005. It is a member of a new class of tridentate iron chelators, the N-substituted bis-hydroxyphenyl-triazoles. Metabolism and elimination of deferasirox are primarily by glucuronidation followed by hepatobiliary excretion into the faeces. Approved in more than 70 countries including the US and Europe, Exjade is the first once-daily oral iron chelator approved for use in patients with chronic transfusional iron overload who have a wide range of underlying anaemias.

The launch of the emerging therapies is expected to significantly impact the Beta-thalassemia treatment scenario in the upcoming years:-
Drugs covered
1 LentiGlobin BB305
2 PTG-300
3 ACE-011 (Sotatercept)
4 Mitapivat
5 IONIS TMPRSS6 LRx
6 VIT 2763
7 Emeramide
And many others

The key players in Beta-thalassemia market are:
1. BlueBird Bio
2. Protagonist Therapeutics
3. Acceleron Pharma
4. Celgene Corporation
5. Agios Pharmaceuticals
6. Ionis Pharmaceuticals
7. Vifor Pharma
8. EmeraMed
And many others

Table of contents
1 Key Insights
2 Executive Summary of Beta Thalassemia
3 SWOT Analysis for Beta Thalassemia
4 Beta Thalassemia Market Overview at a Glance
5 Beta-thalassemia Disease Background and Overview
6 Beta-thalassemia Epidemiology and Patient Population
7 Country Wise-Epidemiology of Beta Thalassemia
7.1 The United States
7.2 EU5 Countries
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 Spain
7.2.5 The UK
7.3 Japan
8 Beta-thalassemia Treatment and Management
9 Case Study
10 Unmet Needs
11 Beta-thalassemia Marketed Products
11.1 Desferal: Novartis
11.2 Exjade: Novartis
11.3 Ferrirpox (deferiprone): Apotex
11.4 ACE-536: Acceleron Pharma/Celgene Corporation
12 Beta-thalassemia Emerging Therapies
12.1 LentiGlobin BB305: BlueBird Bio
12.2 PTG-300: Protagonist Therapeutics
12.3 ACE-011 (Sotatercept): Acceleron Pharma/Celgene Corporation
12.4 Mitapivat: Agios Pharmaceuticals
12.5 IONIS TMPRSS6 LRx: Ionis Pharmaceuticals
12.6 VIT 2763: Vifor Pharma
12.7 Emeramide: EmeraMed
13 Other Promising Candidates
13.1 OTL-300: Orchard Therapeutics
13.2 ST-400: Sangamo Therapeutics/Sanofi
13.3 CTX001: CRISPR Therapeutics/Vertex Pharmaceuticals
14 Other Products in the News
14.1 DST-0509 : DisperSol Technologies
14.2 ATIR201: Kiadis
14.3 Ruxolitinib: Incyte Corporation/ Novartis
14.4 EDIT-301: Editas Medicine
14.5 Global Blood Therapeutics/ Syros Pharmaceuticals
15 Discontinued Therapies
15.1 LJPC-401: La Jolla Pharmaceutical Company
16 Beta Thalassemia: 6 Major Market Analysis
17 Beta-thalassemia Market Outlook by Country
17.3 Germany Market Size
17.4 France Market Size
17.5 Italy Market Size
17.6 Spain Market Size
17.7 The UK Market Size
18 Market Access and Reimbursement Landscape
19 Market Drivers
20 Market Barriers
21 Appendix
22 DelveInsight Capabilities
23 Disclaimer
24 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 06/15/2020 -- Trichotillomania Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Trichotillomania Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. Trichotillomania, a relatively rare condition with estimates ranging from less than 1% to as high as 4% of the US population.
2. There will be 25 million people with Trichotillomania in the United States if even 1% of the US population has the disease.
3. Trichotillomania is more common in females than in males.

Key benefits of the report
1. Trichotillomania market report covers a descriptive overview and comprehensive insight of the Trichotillomania epidemiology and Trichotillomania market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Trichotillomania market report provides insights into the current and emerging therapies.
3. Trichotillomania market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Trichotillomania market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Trichotillomania market.

Request for sample pages

Individuals with trichotillomania do not or rarely seek psychological or psychiatric treatment for their condition. Patients avoid seeking treatment due to social embarrassment.

The evidence base for psychotherapy for trichotillomania is less but hints the use of behavioural therapy. Behavioural therapy for trichotillomania has generally used habit reversal therapy (HRT) and has sometimes included components of acceptance and commitment therapy and dialectical behaviour therapy as well. There are a few controlled studies of behavioural therapy, using HRT alone or with other components, for trichotillomania. In terms of medication options, there are currently no pharmacotherapies that would be universally accepted as first-line treatments for trichotillomania.

Psychotherapy: Habit reversal therapy (HRT) is conducted every week, although higher severity of the disorder may necessitate more frequent sessions. HRT as the first-line psychotherapy treatment for these disorders.

Pharmacotherapy: In terms of medication options, there are currently no pharmacotherapies that would be universally accepted as first-line treatments for trichotillomania.

Commonly used medications are fluoxetine (Prozac), fluvoxamine (Luvox), sertraline (Zoloft), paroxetine (Paxil), clomipramine (Anafranil) valproate (Depakote), lithium carbonate (Lithobid, Eskalith). In terms of glutamate agents, N- acetylcysteine (NAC) has demonstrated benefit in a double-blind placebo-controlled study for trichotillomania using a dose of 1200mg twice a day and giving it approximately nine weeks to work.

The launch of the emerging therapies is expected to significantly impact the Trichotillomania treatment scenario in the upcoming years:-
Drugs covered
- SXC-2023
And many others

The key players in Trichotillomania market are:
- Promentis Pharmaceuticals
And many others

Table of contents
1. Report Introduction
2. Trichotillomania Market Share at a glance
3. Trichotillomania Disease Background and Overview
4. Trichotillomania Epidemiology and Patient Population
5. Country Wise Epidemiology of Trichotillomania
5.1. United States
5.2. EU5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
6. Trichotillomania Current Treatment & Medical Practices
7. Trichotillomania Emerging Therapeutics
7.1. Key Cross Competition
7.2. SXC-2023: Promentis Pharmaceuticals
8. Trichotillomania Market Size
9. Region-Wise Market size of Trichotillomania (2017-2030)
9.1. United States
9.2. EU-5
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. Spain
9.2.5. United Kingdom
9.3. Japan
10. Market Drivers
11. Market Barriers
12. Appendix
13. Trichotillomania Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Buisness Reearch LLP

Albany, NY -- (SBWIRE) -- 06/11/2020 -- Geographic Atrophy Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Geographic Atrophy Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. Geographic Atrophy causes impaired visual function and affects more than 5 million people worldwide, including 22% of people over 90 years old.
2. Geographic Atrophy prevalence was 6.6% among elderly Japanese with age-related macular degradation (AMD).
3. Males and females are equally affected by Geographic Atrophy.

Key benefits of the report
1. Geographic Atrophy market report covers a descriptive overview and comprehensive insight of the Geographic Atrophy epidemiology and Geographic Atrophy market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Geographic Atrophy market report provides insights into the current and emerging therapies.
3. Geographic Atrophy market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Geographic Atrophy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Geographic Atrophy market.

Request for sample pages

Contrary to neovascular (n-AMD), characterized by acute vision loss and anatomical and functional improvement after treatment, Geographic Atrophy is a slowly but inexorably progressive disease that causes irreversible blindness over time.

The primary goal of Geographic Atrophy treatment is to stop or slow disease progression to prevent vision loss. However, strategies for management of age-related macular degradation (AMD) include low visual aids and preventive measures with the antioxidants exists currently. The mainstay Geographic Atrophy treatment includes over-the-counter high-dose antioxidants and minerals (AREDS supplements) to make the affected individuals clinically comfortable.

With no approved therapies for Geographic Atrophy, over-the-counter AREDS supplements such as high-dose antioxidants and minerals, vitamins C and E and beta-carotene are mostly being recommended to Geographic Atrophy patients. However, they are not effective in reducing Geographic Atrophy progression till now as per the outcomes obtained from several studies.

The advancements in imaging and a new understanding of disease mechanisms based on molecular and genetic models have paved the way for the development of novel experimental treatment options for GA that aim to cater to a thus far mostly unmet need. Over the past two decades, there has been much interest in the role that immune dysfunction, in particular inappropriate complement cascade activation, plays in the aetiology of age-related macular degradation (AMD).

Presently there are still no proven Geographic Atrophy treatments that slow progression once it is established. However, several new groups of drugs, including those targeting the complement cascade and agents considered as neuroprotective, have shown some promising results. Trials of these novel interventions have been conducted in participants with the presence of significant areas of Geographic Atrophy already.

The launch of the emerging therapies is expected to significantly impact the Geographic Atrophy treatment scenario in the upcoming years:-
Drugs covered
- APL-2
- Iluvien
- IONIS-FB-Lrx
And many others

The key players in Geographic Atrophy market are:
- Apellis Pharmaceuticals
- Alimera Sciences
- Ionis Pharmaceuticals
And many others

Table of contents
1. Report Introduction

2. Geographic Atrophy Market Overview at a Glance

3. Geographic Atrophy Disease Background and Overview

4. Geographic Atrophy Epidemiology and Patient Population

5. Geographic Atrophy Country-Wise Epidemiology

6. United States

7. EU–5 Countries

7.1. Assumptions and Rationale

7.2. Germany

7.3. France

7.4. Italy

7.5. Spain

7.6. United Kingdom

7.7. Japan

8. Geographic Atrophy Treatments and Medical Practices

9. Unmet Needs

10. Geographic Atrophy Emerging Therapies

10.1. APL-2: Apellis Pharmaceuticals

10.2. Iluvien: Alimera Sciences

10.3. IONIS-FB-Lrx: Ionis Pharmaceuticals

11. Geographic Atrophy Market Size

12. 7MM Geographic Atrophy Country-Wise Market Analysis

13. United States Market Size

14. EU5 Market Size

14.1. Germany: Market Size

14.2. France: Market Size

14.3. United Kingdom: Market Size

14.4. Spain: Market Size

14.5. Italy: Market Size

15. Japan: Market Size

16. Geographic Atrophy Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 06/10/2020 -- Mucosa-Associated Lymphoid Tissue Lymphoma Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Mucosa-Associated Lymphoid Tissue Lymphoma (MALT) Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The estimated incidence of gastric lymphoma was approximately 0.3–0.8/100,000 people in Europe.
2. In the United States, the incidence of gastric lymphoma was around 0.38/100,000 people.
3. The disease mainly affects adults above 60 years, with a slight predominance in females.

Key benefits of the report
1. Mucosa-Associated Lymphoid Tissue Lymphoma market report covers a descriptive overview and comprehensive insight of the Mucosa-Associated Lymphoid Tissue Lymphoma epidemiology and Mucosa-Associated Lymphoid Tissue Lymphoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. MALT Lymphoma market report provides insights into the current and emerging therapies.
3. MALT Lymphoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. MALT Lymphoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Mucosa-Associated Lymphoid Tissue Lymphoma market.

Request for sample pages

MALT Lymphoma Treatment is tailored to the type, stage, and grade. Most slow-growing, localized MALT lymphomas respond better to treatment. Local therapies like radiation therapy or surgery are used with early-stage MALT lymphomas that occur in areas other than the stomach. More advanced MALT lymphomas (stage 3 or 4) are usually treated with chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) or CVP (cyclophosphamide, vincristine and prednisolone), or with single-agent chemotherapy such as chlorambucil. The monoclonal antibody, rituximab may also be used, either on its own or in combination with chemotherapy.

Surgery is often required when complications like significant haemorrhage, pyloric stenosis, or perforation (cases with massive infiltration and chemotherapy) occur. Thus, moderate-dose radiotherapy (30 Gy) including stomach and peri-gastric lymph nodes offers excellent results with a remission rate of 93–100%.

Chemotherapy and Rituximab immunotherapy, as the first-line therapy, could be used in all stages of the disease or a combination of both. The combination of Rituximab (anti-CD20 monoclonal antibodies) and oral alkylating agents (Chlorambucil, Cyclophosphamide) or purine nucleoside analogues (Cladribine, Fludarabine) have superior results in the remission of the disease and survival rates.

The launch of the emerging therapies is expected to significantly impact Mucosa-Associated Lymphoid Tissue Lymphoma treatment scenario in the upcoming years:-
Drugs covered
- ziv-aflibercept

- BKM120 & Rituximab

- Rituxan/Bendamustine/PCI-32765

- Brentuximab Vedotin + Rituximab
And many others

The key players in MALT Lymphoma market are:
- Regeneron Pharmaceuticals
- Kami Maddocks
- Novartis
- Pharmacyclics LLC
- Seattle Genetics
And many others

Table of contents
1. MALT Lymphoma Report Introduction

2. Mucosa-associated Lymphoid Tissue Lymphoma Market Overview at a Glance

3. Disease Background and Overview: Mucosa-associated Lymphoid Tissue Lymphoma

4. MALT Lymphoma Epidemiology and Patient Population

4.1. Assumptions and Caveats

4.2. 7MM Incident cases of MALT Lymphoma (2017–2030)

4.3. 7MM Incident cases of Gastric MALT Lymphoma (2017–2030)

4.4. Gender-specific cases of Mucosa-associated Lymphoid Tissue Lymphoma (2017–2030)

4.5. Age-specific cases of Mucosa-associated Lymphoid Tissue (MALT) Lymphoma (2017–2030)

4.6. Mucosa-associated Lymphoid Tissue Lymphoma: Country-Wise Epidemiology

4.7. United States

4.8. EU-5

4.9. Assumptions and Rationale

4.10. Germany

4.11. France

4.12. Italy

4.13. Spain

4.14. United Kingdom

4.15. Japan

5. MALT Lymphoma Treatments & Medical Practices

6. MALT Lymphoma Emerging Therapies

7. Key Competitors

7.1. ziv-aflibercept: Regeneron Pharmaceuticals

7.2. BKM120 & Rituximab: Kami Maddocks in collaboration with Novartis

7.3. Rituxan/Bendamustine/PCI-32765: Kami Maddocks in collaboration with Pharmacyclics LLC.

7.4. Brentuximab Vedotin + Rituximab: Northwestern University in collaboration with Seattle Genetics, Inc.

8. Mucosa-associated Lymphoid Tissue Lymphoma Market Size

9. 7MM Mucosa-associated Lymphoid Tissue Lymphoma: Country-Wise Market Analysis

10. United States Market Size

11. Germany Market Size

12. France Market Size

13. United Kingdom Market Size

14. Spain Market Size

15. Italy Market Size

16. Japan Market Size

17. MALT Lymphoma Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Albany, NY -- (SBWIRE) -- 06/09/2020 -- Alcoholic Hepatitis Market Insights, Epidemiology and Market Forecast-2030

DelveInsight launched a new report on Alcoholic Hepatitis Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. Nearly 50% of patients with Alcoholic Hepatitis have established cirrhosis at the time of clinical presentation.
2. The typical age of Alcoholic Hepatitis patients is between 40 and 50 years, with the majority occurring before the 60 years.
3. Around 10–50% of patients with alcoholic hepatitis have a high mortality rate and another 5–10% develop a prolonged illness which leads to death.

Key benefits of the report
1. Alcoholic Hepatitis market report covers a descriptive overview and comprehensive insight of the Alcoholic Hepatitis epidemiology and Alcoholic Hepatitis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Alcoholic Hepatitis market report provides insights into the current and emerging therapies.
3. Alcoholic Hepatitis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Alcoholic Hepatitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Alcoholic Hepatitis market.

Request for sample pages

Patients with alcoholic hepatitis often suffer from acute malnutrition resulting from loose eating habits, alcohol-related diarrhoea, decreased small bowel absorption capacity, anorexia, and a disproportionate catabolic state that is directly related to increased mortality.

Some specific therapies that are used for the treatment of alcoholic hepatitis are corticosteroids and pentoxifylline.

Pentoxifylline, a non-selective phosphodiesterase inhibitor, which raises intracellular concentrations of adenosine 3?, 5?-cyclic monophosphate (cAMP) and guanosine 3?, 5?-cyclic monophosphate (cGMP). It is believed to enhance results in alcoholic hepatitis through downregulation of pro-inflammatory cytokines (e.g., TNF-?).

Thus, despite the best standard of care and steroids, the majority of patients either do not respond to steroids or are not eligible for steroids. A vast majority of steroid intolerant, ineligible, unresponsive alcoholic hepatitis patients are left with no specific available alcoholic hepatitis treatment options.

Overall, the alcoholic hepatitis market is expected to grow in the coming years with improved clinical trials, increasing awareness among ordinary people, boost in research activities, along with a rise in its incident cases.
The launch of the emerging therapies is expected to significantly impact Alcoholic Hepatitis treatment scenario in the upcoming years:-
Drugs covered
- DS102
- DUR-928
And many others

The key players in Alcoholic Hepatitis market are:
. Afimmune
. Durect
And many others

Table of contents
1. Report Introduction
2. Alcoholic Hepatitis Market Overview at a Glance
3. Executive Summary of Alcoholic Hepatitis
4. Alcoholic Hepatitis Methodology
5. Organizations
6. Alcoholic Hepatitis Disease Background and Overview
7. Alcoholic Hepatitis Epidemiology and Patient Population
8. Alcoholic Hepatitis Country-Wise Epidemiology
8.1. United States
8.2. EU-5
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. Spain
8.2.5. United Kingdom
8.3. Japan
9. Alcoholic Hepatitis Treatment and Medical Practices
10. Unmet Needs
11. Key Alcoholic Hepatitis Emerging Therapies
11.1. Key Competitors
11.2. DS102: Afimmune
11.3. DUR-928: Durect
12. Alcoholic Hepatitis Market Size
13. 7MM Alcoholic Hepatitis Country-Wise Market Analysis
13.1. United States
13.2. Germany
13.3. France
13.4. United Kingdom
13.5. Spain
13.6. Italy
13.7. Japan
14. Market Drivers
15. Market Barriers
16. SWOT Analysis
17. Case studies
18. Market Access and Reimbursement
19. Bibliography
20. Alcoholic Hepatitis Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 06/08/2020 -- Excessive Daytime Sleepiness Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Excessive Daytime Sleepiness Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. There are 19.5% of US adults that are suffering from moderate to severe excessive daytime sleepiness.
2. It is estimated that 20–25% of people with narcolepsy have all four symptoms, including excessive daytime sleepiness, abrupt loss of muscle function, sleep paralysis and hallucinations.
3. The prevalence of Excessive Daytime Sleepiness is more in individuals aged between 20 and 49 years.

Key benefits of the report
1. Excessive Daytime Sleepiness market report covers a descriptive overview and comprehensive insight of the Excessive Daytime Sleepiness epidemiology and Excessive Daytime Sleepiness market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Excessive Daytime Sleepiness market report provides insights into the current and emerging therapies.
3. Excessive Daytime Sleepiness market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Excessive Daytime Sleepiness market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Excessive Daytime Sleepiness market.

Request for sample pages

Excessive Daytime Sleepiness is a highly prevalent complaint associated with significant adverse effects on health, workplace and academic performance, absenteeism, and overall health and safety. Excessive Daytime Sleepiness treatment is based on the underlying cause of the condition. Traditionally, amphetamine-like stimulants (i.e., dopaminergic release enhancers) have been used for clinical management to improve the disease, along with tricyclic antidepressants, which have been used as anticataplectics.

The underlying cause of the disease determines the type of Excessive Daytime Sleepiness treatment given to the patients. These include non- pharmacologic approaches; pharmacologic treatments (sympathomimetic agents; caffeine); Central Nervous Stimulants [Methylphenidate (Ritalin, Ritalin SR, Methylin, Methylin ER), Mixed Amphetamine Salts (Adderall IR, Adderall XR), Dextroamphetamine (Dexedrine, Dexedrine SR), Lisdexamfetamine (Vyvanse)] and another rapid eye movement (REM) sleep medications.

In the case of sleep apnea, a continuous positive airway pressure (CPAP) machine can be used. Medication can also be recommended to patients who are suffering from narcolepsy to make them remain awake. Shift workers may also benefit from medication if adjusting sleep habits does not help, or if rotating schedules make it challenging to sleep sufficiently. In case of failure, behavioural changes to improve sleep, medication may be an option.

Previously approved therapeutics includes Modafinil (Provigil) and armodafinil (Nuvigil), which are the possible medications for Excessive Daytime Sleepiness treatment.

Drugs covered in the report
Marketed Therapies
- Sunosi: Jazz Pharmaceuticals
And many others

Emerging Therapies
- JZP-258: Jazz Pharmaceuticals
And many others

Table of contents
1. Excessive Daytime Sleepiness Report Introduction
2. Executive Summary
3. SWOT Analysis
4. Excessive Daytime Sleepiness Market Overview at a Glance
5. Excessive Daytime Sleepiness Disease Background and Overview
6. Excessive Daytime Sleepiness Epidemiology and Patient Population
7. Excessive Daytime Sleepiness Country-wise Epidemiology
7.1. United States
7.2. EU-5
7.3. Germany
7.4. France
7.5. Italy
7.6. Spain
7.7. United Kingdom
7.8. Japan
8. Unmet Needs
9. Excessive Daytime Sleepiness Treatments & Medical Practices
10. Excessive Daytime Sleepiness Marketed Therapies
10.1. Key Cross Competition
10.2. Sunosi: Jazz Pharmaceuticals
11. Excessive Daytime Sleepiness Emerging Therapies
11.1. Key Cross Competition
11.2. JZP-258: Jazz Pharmaceuticals
12. Excessive Daytime Sleepiness Market Size
13. 7MM Excessive Daytime Sleepiness Country-Wise Market Analysis
13.1. United States Market Size
13.2. Germany Market Size
13.3. France Market Size
13.4. United Kingdom Market Size
13.5. Spain Market Size
13.6. Italy Market Size
13.7. Japan Market Size
14. Market Barriers
15. Market Drivers
16. Excessive Daytime Sleepiness Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Albany, NY -- (SBWIRE) -- 06/05/2020 -- Alzheimer's Disease Market Insights, Epidemiology and Market Forecast-2030

DelveInsight launched a new report on Alzheimer's Disease Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. Alzheimer's Disease affects an estimated 6.08 million people in the United States.
2. Approximately 200,000 people younger than 65 years constitute the younger-onset population of Alzheimer's Disease in the US.
3. The females show a higher proportion of Alzheimer's Disease Prevalence as compared to males in the 7MM.

Key benefits of the report
1. Alzheimer's Disease market report covers a descriptive overview and comprehensive insight of the Alzheimer's Disease epidemiology and Alzheimer's Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Alzheimer's Disease market report provides insights into the current and emerging therapies.
3. Alzheimer's Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Alzheimer's Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Alzheimer's Disease market.

Request for sample pages

Alzheimer's disease attacks the cells of the brain and neurotransmitters, affecting the way brain functions, memory and behaviour. There is no known cure for the disease, and current approaches focus on helping people maintain mental function, manage behavioural symptoms, and slow down specific problems, such as memory loss. Two categories of drugs are approved for Alzheimer's disease treatment: cholinesterase inhibitors and partial N-methyl D-aspartate (NMDA) antagonists.

Cholinesterase inhibitors act by increasing the level of acetylcholine; a chemical used by nerve cells to communicate with each other and is vital for learning, memory, and cognitive functions. Of this category, three drugs: Donepezil (Aricept), Rivastigmine (Exelon), and Galantamine (Razadyne) are FDA-approved for the treatment of Alzheimer's disease and are used to treat mild-to-moderate Alzheimer's (donepezil can be used for severe Alzheimer's as well). Donepezil can be used in all stages of Alzheimer disease. Galantamine and rivastigmine are approved for treatment in mild-to-moderate Alzheimer disease only. Donepezil and galantamine are rapid, reversible inhibitors of acetylcholinesterase. Rivastigmine is a slow, reversible inhibitor of acetylcholinesterase and butyrylcholinesterase. Most common side effects of cholinesterase inhibitors are gastrointestinal-like nausea, vomiting, and diarrhoea.

Partial N-Methyl D-aspartate (NMDA) antagonist includes memantine. Memantine (Namenda) is used to treat moderate-to-severe Alzheimer's disease. However, these drugs do not change the underlying disease process. They are useful for some but not all people and may help only for a limited time. The FDA has also approved Aricept and Namzaric, a combination of Namenda and Aricept, for the treatment of moderate-to-severe Alzheimer's disease. Dizziness, body aches, headache, and constipation are common side effects. It can be taken in combination with cholinesterase inhibitors.

The launch of the emerging therapies is expected to significantly impact Alzheimer's Disease treatment scenario in the upcoming years:-
Drugs covered
1. AGB101
2. Bryostatin-1
3. COR388 HCL
4. Eltoprazine
5. ALZT-OP1
6. Brexpiprazole
7. AKST/GRF6019
8. AXS-05
9. Tricaprilin
10. TRx0237
11. RO7105705
12. Azeliragon (TTP488)
And many others

The key players in Alzheimer's Disease market are:
1. AgeneBio
2. Neurotrope Bioscience
3. Cortexyme
4. Amarantus Bioscience Holdings
5. AZ Therapies
6. Otsuka Pharmaceutical
7. Alkahest
8. Axsome Therapeutics
9. Cerecin
10. TauRx Therapeutics
11. Genentech
12. vTv Therapeutics

And many others

Table of contents

1. Report Introduction

2. Alzheimer's Disease Market Overview at a Glance

3. Alzheimer's Disease Disease Background and Overview

4. Alzheimer's Disease Epidemiology and Patient Population

5. Epidemiology of Alzheimer's Disease by Countries (2017–2030)

5.1. United States- Epidemiology (2017–2030)

5.2. EU-5 - Epidemiology (2017–2030)

5.2.1. Assumptions and Rationale

5.2.2. Germany

5.2.3. France

5.2.4. Italy

5.2.5. Spain

5.2.6. United Kingdom

5.3. Japan

6. Alzheimer's Disease Treatments & Medical Practices

7. Alzheimer's Disease Marketed Products

7.1. Aricept: Eisai

7.2. Exelon: LTS Lohmann Therapie-Systeme/Novartis

7.3. Oligomannate: Green Valley Pharmaceuticals

8. Alzheimer's Disease Emerging Therapies

8.1. Key Cross Competition

8.2. AGB101: AgeneBio

8.3. Bryostatin-1: Neurotrope Bioscience

8.4. COR388 HCL: Cortexyme

8.5. Eltoprazine: Amarantus Bioscience Holdings

8.6. ALZT-OP1: AZ Therapies

8.7. Brexpiprazole: Otsuka Pharmaceutical

8.8. AKST/GRF6019: Alkahest

8.9. AXS-05: Axsome Therapeutics

8.10. Tricaprilin: Cerecin

8.11. TRx0237: TauRx Therapeutics

8.12. RO7105705: Genentech

8.13. Azeliragon (TTP488): vTv Therapeutics

9. Alzheimer's Disease Market Size

10. 7MM: Country-Wise Market Analysis

10.1. United States Market Size

10.2. Germany Market Size

10.3. France Market Size

10.4. Italy Market Size

10.5. Spain Market Size

10.6. United Kingdom Market Size

10.7. Japan Market Size

11. Market Drivers

12. Market Barriers

13. Alzheimer's Disease Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Albany, NY -- (SBWIRE) -- 06/04/2020 -- B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology and Market Forecast-2030

DelveInsight launched a new report on B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report

1. The total incident cases of Non-Hodgkin Lymphoma (NHL) in the 7MM was 166,909 in 2017.

2. Among the 7MM, the highest Incident population of B cell-NHL was in the United States with 61,080 cases in 2017.

3. The most incident age-group for B-cell NHL among the 7MM was 65–74 years in 2017. Patients of age groups 55–64 years were observed to be the second-highest in 2017.

Key benefits of the report

1. B-Cell Non-Hodgkin Lymphoma market report covers a descriptive overview and comprehensive insight of the B-Cell Non-Hodgkin Lymphoma Epidemiology and B-Cell Non-Hodgkin Lymphoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. B-Cell NHL market report provides insights into the current and emerging therapies.

3. B-Cell Non-Hodgkin Lymphoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.

4. B-Cell NHL market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the B-Cell Non-Hodgkin Lymphoma market.

Request for sample pages

"B-cell NHL market size was USD 6,114 million in the 7MM countries in 2017."

There are several treatment options for B-cell lymphoma, which include chemotherapy, radiation, and immunotherapy. The aforementioned B-cell lymphoma treatment modalities have been used, alone or in combination. The choice of treatment for B-cell lymphoma is dependent on the type of B-cell Lymphoma, symptoms, age, and how fast it is growing and whether patients may suffer various patterns of recurrence requiring subsequent lines of rescue therapies.

Rituximab was the first mAb to be approved for the treatment of cancer and the first single-agent approved specifically for refractory B-cell low-grade NHL. Following its initial US FDA approval for low-grade NHL in 1997, it was approved for other subtypes of lymphoma, including DLBCL, CLL, and FL. In February 2002, the first radio-immunotherapeutic agent to receive approval by the FDA. Zevalin is indicated for the treatment of relapsed or low refractory grade, follicular, or transformed B-cell NHL.

The launch of the emerging therapies is expected to significantly impact B-Cell Non-Hodgkin Lymphoma treatment scenario in the upcoming years:-

Drugs covered
1. Tafasitamab
2. Lisocabtagene maraleucel (JCAR017)
3. Enzastaurin Hydrochloride (DB102)
4. Avelumab (Bavencio)
5. Umbralisib (TG-1202)
6. MBCART2019.1

And many others

The key players in B-Cell Non-Hodgkin Lymphoma market are:
1. MorphoSys AG
2. Bristol-Myers Squibb
3. Denovo Biopharma
4. Pfizer
5. Merck
6. TG Therapeutics
7. Miltenyi Biotec

And many others

Table of contents
1. Key Insights
2. Executive Summary of B-cell NHL
3. SWOT Analysis for B-cell NHL
4. B-cell NHL Patient Share of B-cell NHL at a Glance
5. B-cell NHL Market Overview at a Glance
6. B-cell Non-Hodgkin Lymphoma Disease Background and Overview
7. B-cell Non-Hodgkin Lymphoma Epidemiology and Patient Population
8. B-cell Non-Hodgkin Lymphoma Epidemiology Scenario: 7MM
9. United States Epidemiology
10. EU-5 Country-wise Epidemiology
10.1. Germany Epidemiology
10.2. France Epidemiology
10.3. Italy Epidemiology
10.4. Spain Epidemiology
10.5. United Kingdom Epidemiology
11. Japan Epidemiology
12. Current Treatment Practices for B-cell NHL: As per Leukemia & Lymphoma Society (LLS)
13. Unmet Needs
14. B-cell Non-Hodgkin Lymphoma Marketed Products
14.1. Brukinsa (Zanubrutinib): BeiGene
14.2. Polivy (Polatuzumab vedotin): Hoffmann-La Roche
14.3. Venetoclax (ABT199): AbbVie and Roche
14.4. Kymriah (tisagenlecleucel): Novartis
14.5. Copiktra (Duvelisib): Verastem
14.6. Keytruda (Pembrolizumab): Merck Sharp & Dohme
14.7. Yescarta (Axicabtagene ciloleucel; KTE-C19): Gilead Sciences
14.8. Aliqopa (Copanlisib; BAY 80-6946): Bayer
14.9. Calquence (Acalabrutinib): AstraZeneca
14.10. Imbruvica (Ibrutinib): Janssen/Pharmacyclics (AbbVie Company)
14.11. Zydelig (Idelalisib): Gilead Sciences
14.12. Gazyva (Obinutuzumab, GA-101): Genentech (Roche Group)
14.13. Revlimid (lenalidomide): Celgene Corporation
14.14. Velcade (bortezomib): Takeda (Millennium Pharmaceuticals) and Janssen Pharmaceutica
14.15. Zevalin (ibritumomab tiuxetan): Spectrum Pharmaceuticals
14.16. Torisel: Pfizer
15. B-cell Non-Hodgkin Lymphoma Emerging Therapies
15.1. Key Cross
15.2. Tafasitamab (MOR208; formerly XmAb 5574): MorphoSys AG
15.3. Lisocabtagene maraleucel (JCAR017): Bristol-Myers Squibb
15.4. Enzastaurin Hydrochloride (DB102): Denovo Biopharma
15.5. Avelumab (Bavencio): Pfizer/Merck
15.6. Umbralisib (TG-1202): TG Therapeutics
15.7. MBCART2019.1: Miltenyi Biotec
16. B-cell NHL: Seven Major Market Analysis
17. B-cell Non-Hodgkin Lymphoma Market Outlook: 7MM
18. United States Market Size
19. EU-5 Market Size
19.1. Germany Market Size
19.2. France Market Size
19.3. Italy Market Size
19.4. Spain Market Size
19.5. United Kingdom Market Size
20. Japan Market Size
21. Market Access and Reimbursement Scenario of B-cell NHL Therapies
22. Market Drivers
23. Market Barriers
24. Appendix
25. Disclaimer
26. DelveInsight Capabilities
27. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Albany, NY -- (SBWIRE) -- 06/03/2020 -- Chronic Kidney Disease Market Insights, Epidemiology and Market Forecast-2030

DelveInsight launched a new report on Chronic Kidney Disease Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report

1. The total Chronic Kidney Disease prevalent population was 122,704,658 in the 7MM in 2017.

2. The highest prevalent population of Chronic Kidney Disease (CKD) was in the United States, with 35,288,932 cases in 2017.

3. The second most CKD prevalent cases in 7MM were recorded in Japan with 21,183,442 cases in 2017.

Key benefits of the report

1. Chronic Kidney Disease market report covers a descriptive overview and comprehensive insight of the Chronic Kidney Disease epidemiology and Chronic Kidney Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. CKD market report provides insights into the current and emerging therapies.

3. Chronic Kidney Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.

4. CKD market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Kidney Disease market.

Request for sample pages

Chronic kidney disease is one type of kidney disease in which there is a gradual loss of kidney function over months to years. The initial symptoms include leg swelling, feeling tired, vomiting, loss of appetite, and confusion; complications in CKD involve anaemia, bone disease, high blood pressure and increased risk of heart disease. Anaemia is common and is especially prevalent in those requiring hemodialysis. The mechanism of anaemia in CKD are multifactorial and include increased inflammation, reduction in Erythropoietin, and hyperuricemia leading to bone marrow suppression.

There are several types of medications available in the market. Available medicines cannot reverse CKD; however, they are used to treat complications and to slow further kidney damage.

The chronic kidney disease drugs market is categorized based on drug class like Erythropoietin stimulating agents (ESA), Angiotensin-converting-enzyme inhibitors and Angiotensin receptor blockers (ACE-I and ARBs), Antidiabetics, Secondary Hyperparathyroidism Treatment (SHPT), and Urate Lowering Therapies.

Anaemia is prevalent in patients with chronic kidney disease; CKD therapeutic market size is mainly accounted for ESA therapies. These include Epogen (Epoetin alfa) and Aranesp (Darbepoetin alfa) by Amgen, Procrit by Johnson & Johnson and Feraheme by Amag Pharmaceuticals. Another drug marketed by Affymax, Inc. and Takeda Pharmaceutical (Omontys) was withdrawn due to post-marketing surveillance reports of severe hypersensitivity reactions including anaphylaxis, which may be life-threatening or fatal.

Secondary Hyperparathyroidism is an early and significant complication of CKD. Treatment involves suppression of PTH to prevent metabolic bone disease, bone loss, and metabolic complications that may result in marked morbidity and mortality. Appropriate treatment involves suppression of parathyroid hormone (PTH) to normal levels with active vitamin D therapy and phosphate binders. Ergocalciferol or cholecalciferol is used to correct 25-hydroxyvitamin D levels either before or during active vitamin D therapy. Active vitamin D analogues include calcitriol, doxercalciferol, and paricalcitol.

The launch of the emerging therapies is expected to significantly impact Chronic Kidney Disease treatment scenario in the upcoming years:-

Drugs covered
1. Daprodustat
2. Vadadustat
3. Roxadustat

4. FibroGen
5. Empagliflozin
6. Veverimer
7. Dapagliflozin
8. Ziltivekimab
9. Bardoxolone methyl

And many others

The key players in Chronic Kidney Disease market are:
1. GlaxoSmithKline
2. Akebia Therapeutics
3. Astellas Pharma
4. Boehringer Ingelheim
5. Tricida
6. AstraZeneca
7. Corvidia Therapeutics
8. Reata Pharmaceuticals

And many others

Table of contents

1 Key Insights
2 Executive Summary of Chronic Kidney Disease
3 SWOT Analysis for Chronic Kidney Disease
4 Chronic Kidney Disease Market Overview at a Glance
5 CKD Disease Background and Overview
6 Chronic Kidney Disease Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Prevalent Patient Population of Chronic Kidney Disease (CKD)
6.3 The United States
6.4 EU-5
6.4.1 Assumptions and Rationale
6.4.2 Germany
6.4.3 France
6.4.4 Italy
6.4.5 Spain
6.4.6 The United Kingdom
6.5 Japan
7 CKD Treatment and Management
8 Unmet Needs
9 Chronic Kidney Disease Marketed Products
9.1 Epogen (Epoetin alfa): Amgen
9.2 Aranesp (Darbepoetin alfa): Amgen
9.3 Feraheme: Amag Pharmaceuticals
9.4 Parsabiv (etelcalcetide): Amgen
9.5 Sensipar (Cinacalcet): Amgen
9.6 Auryxia: Keryx Biopharmaceuticals
9.7 Paricalcitol (Zemplar): AbbVie
9.8 Velphoro(Sucroferric oxyhydroxide): Vifor Pharma
9.9 Rayaldee (CTAP101): OPKO IP Holdings II, Inc.|OPKO Health, Inc.
9.10 CKD-11101: Chong Kun Dang Pharmaceuticals
10 Chronic Kidney Disease Emerging Therapies
10.1 Daprodustat: GlaxoSmithKline
10.2 Vadadustat: Akebia Therapeutics
10.3 Roxadustat: FibroGen/Astellas Pharma/AstraZeneca
10.4 Empagliflozin: Boehringer Ingelheim
10.5 Veverimer: Tricida
10.6 Dapagliflozin: AstraZeneca
10.7 Ziltivekimab: Corvidia Therapeutics
10.8 Bardoxolone methyl: Reata Pharmaceuticals.
11 CKD 7 Major Market Analysis
12 Market Outlook: 7MM
13 Country-wise Market Size
14 United States
15 EU5 Countries
15.1 Germany
15.2 France
15.3 Italy
15.4 Spain
15.5 United Kingdom
16 Japan
17 Market Access and Reimbursement
19 Market Drivers
20 Market Barriers
21 Appendix
22 DelveInsight Capabilities
23 Disclaimer
24 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 06/02/2020 -- Dilated Cardiomyopathy Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Dilated Cardiomyopathy Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total Dilated Cardiomyopathy prevalent population in the 7MM was 2,486,633 in 2017.
2. Among the European 5 countries, Germany had the highest diagnosed cases of Dilated cardiomyopathy with 81,571 cases in 2017.
3. Males are more affected by Dilated Cardiomyopathy as compared to females.

Key benefits of the report
1. Dilated Cardiomyopathy market report covers a descriptive overview and comprehensive insight of the Dilated Cardiomyopathy epidemiology and Dilated Cardiomyopathy market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Dilated Cardiomyopathy market report provides insights into the current and emerging therapies.
3. Dilated Cardiomyopathy market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Dilated Cardiomyopathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Dilated Cardiomyopathy market.

Request for sample pages

"Dilated cardiomyopathy market size in the 7MM was USD 244 million in 2017."

There are minimal options for medications that can be used for Dilated Cardiomyopathy treatment. Currently, there is no curative treatment available for the disease, and the current Dilated cardiomyopathy treatment options are off-label therapies like beta-blockers, angiotensin receptor-neprilysin inhibitors, angiotensin-converting enzyme inhibitors (ACEi), aldosterone antagonists and diuretics are used for symptomatic relief.

Dilated cardiomyopathy Treatment aims to control symptoms and reduce complications of heart failure and improving cardiac function. Treatment for Dilated cardiomyopathy can be advised in order to improve blood flow and prevent further damage to the heart. It focused on dimension and function, arrhythmia surveillance and treatment, and reducing congestive symptoms. Thus the combination of medications and implantable devices such as pacemakers is advisable. In advanced disease, surgery might be required with either heart transplantation and implantation of long-term mechanical circulatory support.

The launch of the emerging therapies is expected to significantly impact Dilated Cardiomyopathy treatment scenario in the upcoming years:-

Drugs covered
1. PF-07265803/ARRY-371797/ARRY-797
2. Ixmyelocel-T
3. BC007
4. Ifetroban
5. Danicamtiv/MYK-491
6. CAP-1002
And many others

The key players in Dilated Cardiomyopathy market are:
1. Pfizer
2. Vericel
3. Berlin Cures GmbH
4. Cumberland Pharmaceuticals
5. MyoKardia
6. Capricor Therapeutics
And many others

Table of contents
1 Key Insights
2 Executive Summary of Dilated Cardiomyopathy
3 SWOT Analysis of Dilated Cardiomyopathy
4 Dilated Cardiomyopathy Market Overview at a Glance
5 Dilated Cardiomyopathy Disease Background and Overview
6 Dilated Cardiomyopathy Diagnosis
7 Dilated Cardiomyopathy Epidemiology and Patient Population
8 The United States Epidemiology
9 EU-5 Epidemiology
9.1 Germany
9.2 France
9.3 Italy
9.4 Spain
9.5 The United Kingdom
10 Japan Epidemiology
11 Dilated Cardiomyopathy Treatment
12 Unmet Needs
13 Patient Journey of Dilated Cardiomyopathy
14 Dilated Cardiomyopathy Marketed Therapy
14.1 Corlanor (ivabradine): Amgen
15 Dilated Cardiomyopathy Emerging Therapies
15.1 PF-07265803/ARRY-371797/ARRY-797: Pfizer
15.2 Ixmyelocel-T: Vericel
15.3 BC007: Berlin Cures GmbH
15.4 Ifetroban: Cumberland Pharmaceuticals
15.5 Danicamtiv/MYK-491: MyoKardia
15.6 CAP-1002: Capricor Therapeutics
16 Conjoint Analysis of Dilated Cardiomyopathy
17 Dilated Cardiomyopathy 7 Major Market Analysis
18 Dilated Cardiomyopathy Market Outlook in the 7MM
19 The United States: Market Size
20 EU-5 countries: Market Size
20.1 Germany Market Size
20.2 France Market Size
20.3 Italy Market Size
20.4 Spain Market Size
20.5 The United Kingdom Market Size
21 Japan: Market Size
22 Access and Reimbursement Overview of Dilated Cardiomyopathy
23 Market Drivers
24 Market Barriers
25 Appendix
26 DelveInsight Capabilities
27 Disclaimer
28 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 06/01/2020 -- Osteoporosis Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Osteoporosis Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total diagnosed prevalent population of osteoporosis in the seven major markets was found to be 28,097,783 cases in 2017.
2. The total diagnosed prevalent population of Osteoporosis in the United States was found to be 6,380,754 cases in 2017.
3. Osteoporosis is more in females as compared to males.

Key benefits of the report
1. Osteoporosis market report covers a descriptive overview and comprehensive insight of the Osteoporosis epidemiology and Osteoporosis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Osteoporosis market report provides insights into the current and emerging therapies.
3. Osteoporosis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Osteoporosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Osteoporosis market.

Request for sample pages

"Osteoporosis market size in the seven major markets was 9,442.73 USD Million in 2017".

Osteoporosis treatment involves treating and preventing fractures and using medicines to strengthen the weak bones. For patients, who are at high risk, drug treatments are required to decrease the risk of broken bones due to osteoporosis effectively. Osteoporosis Treatments have been shown to lessen the risk of hip fracture by up to 40%, vertebral fractures by 30-70% and, with some medications, decrease the risk for non-vertebral fractures by 15-20%.

The treatment landscape of osteoporosis comprises majorly of pharmacological therapies, which is further characterized as anti-resorptive agents (i.e., bisphosphonates, estrogen agonist/antagonists (EAAs), estrogens, calcitonin, and denosumab), anabolic agents (i.e., teriparatide and abaloparatide), and mixed agents (i.e., Romosozumab). Apart from the mentioned pharmacotherapies, there are several other anti-resorptive treatment options to treat osteoporosis, such as estrogen replacement and selective estrogen receptor modulators, which further comprises of raloxifene, lasofoxifene, and bazedoxifene. Also, few dietary supplements such as calcium and vitamin D also provide benefit to patients with osteoporosis.

The launch of the emerging therapies is expected to significantly impact the Osteoporosis treatment scenario in the upcoming years:-
Drugs covered
1. Alendronate
2. Zoledronic Acid
3. NaQuinate (Osteopura)
And many others

The key players in Osteoporosis market are:
1. Amgen
2. Haoma Medica
And many others

Table of contents
1. Key Insights
2. Osteoporosis Market Overview at a Glance
3. Disease Background and Overview: Osteoporosis
4. Recognized Establishments
4.1.1. United States
4.1.2. Europe
4.1.3. Japan
5. Osteoporosis Epidemiology and Patient Population
6. Country Wise- Osteoporosis Epidemiology
6.1. United States
6.2. EU5 Countries
6.3. Germany
6.4. France
6.5. Italy
6.6. Spain
6.7. United Kingdom
6.8. Japan
7. Osteoporosis Treatment
8. Endocrine Society: 2019
9. National Osteoporosis Guideline Group (NOGG): 2018
10. American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: 2017
11. American College of Physicians (ACP): 2017
12. Unmet Needs
13. Osteoporosis Marketed Drugs
13.1. Marketed Drugs Key-cross Competition
13.2. Evenity (Romosozumab-aqqg): Amgen
13.3. Prolia (Denosumab): Amgen
13.4. Fablyn (Lasofoxifene): Pfizer
13.5. Duavee (conjugated estrogens/bazedoxifene): Pfizer
13.6. Tymlos (abaloparatide): Radius Health
13.7. Bijuva (estradiol and progesterone): Therapeutics MD
13.8. Boniva (ibandronate sodium): Roche
13.9. Reclast (zoledronic acid): Novartis Pharmaceuticals
13.10. Forteo/Forsteo (Teriparatide): Eli Lilly
13.11. Bonsity (PF708): Pfenex
14. Osteoporosis Emerging Drugs
14.1. Key Cross Competition
14.2. Alendronate/Zoledronic Acid: Amgen
14.3. NaQuinate (Osteopura): Haoma Medica
15. What Experts Say?
16. Osteoporosis: 7 Major Market Analysis
16.1. Key Findings
16.2. Market Size of Osteoporosis in the 7MM
17. The United States Market Outlook
17.1. United States
18. EU-5 Countries: Market Outlook
18.1. Germany
18.2. France
18.3. Italy
18.4. Spain
18.5. United Kingdom
19. Japan: Market Outlook
20. Case Reports
21. Market Drivers
22. Market Barriers
23. Appendix
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 05/29/2020 -- Prostate Cancer Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Prostate Cancer Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total Prostate Cancer prevalent cases in the 7MM were observed to be 6,742,385 cases in 2017.
2. The highest number of prevalent cases of Prostate Cancer was observed in the United States with 3,170,339 cases in 2017.
3. In EU-5 countries, the highest number of diagnosed prevalent cases of Prostate Cancer was found in Germany with 360,916 cases in 2017.

Key benefits of the report
1. Prostate Cancer market report covers a descriptive overview and comprehensive insight of the Prostate Cancer epidemiology and Prostate Cancer market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Prostate Cancer market report provides insights into the current and emerging therapies.
3. Prostate Cancer market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Prostate Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Prostate Cancer market.

Request for sample pages

"Prostate Cancer therapeutic market in seven major markets was found to be USD 6,798 million in 2017."

Many Prostate Cancer treatment options are available to treat this condition in the seven major markets. Besides active surveillance, Radical Prostatectomy (RP) is also suggested. Apart from this, Radiation therapy is an effective Prostate Cancer treatment. Radiation can be recommended from outside of the body (External Beam Radiation Therapy (EBRT)) or radioactive sources can be placed inside the body within or near cancer or the organ containing cancer (brachytherapy), which is often called an implant or seeds. Several key factors are taken into consideration, such age of the patient, previous medical history, health status, and others for Prostate Cancer treatment option to a patient.

Furthermore, some patients receive hormone therapy before, during, and sometimes after radiation treatment. Hormone therapy mainly used to control prostate cancer by blocking the body's production of the male sex hormone testosterone (androgen). It is accomplished using a combination of luteinizing hormone-releasing hormone (LHRH) agonist and a non-steroidal antiandrogen; for this reason, hormone therapy is known as androgen deprivation.

The launch of the emerging therapies is expected to significantly impact Prostate Cancer treatment scenario in the upcoming years:-

The key players in Prostate Cancer market are
1. Lynparza (Olaparib): AstraZeneca/ Merck Sharp & Dohme
2. Opdivo (nivolumab): Bristol-Myers Squibb
3. 177Lu-PSMA-617: Novartis
4. Relugolix: Myovant Sciences/Takeda
5. HC-1119: Hinova Pharmaceuticals
6. Seviteronel (VT-464): Innocrin Pharmaceutical
7. PROSTVAC-V/F: Bavarian Nordic
8. ODM-208: Orion Pharma
9. Sacituzumab Govitecan (IMMU-132): Immunomedics
10. Keytruda (Pembrolizumab/MK-3475): Merck Sharp & Dohme
11. Ipatasertib (RG7440): Hoffmann-La Roche
12. Talazoparib: Pfizer/Astellas Pharma
13. Capivasertib (AZD5363): AstraZeneca
14. AZD4635: AstraZeneca
15. PRX302 (topsalysin): Sophiris Bio
16. Pamiparib (BGB-290): BeiGene
17. Enoblituzumab (MGA271): MacroGenics
18. Tisotumab Vedotin: Genmab
19. Dupilumab: Regeneron Pharmaceuticals
20. Rubraca (Rucaparib): Clovis Oncology
21. Niraparib: Janssen Research & Development
22. Proxalutamide (GT0918): Suzhou Kintor Pharmaceutical
23. Abemaciclib (LY2835219): Eli Lilly and Company
24. Tomivosertib (eFT508): eFFECTOR Therapeutics
25. Onvansertib: Trovagene
26. RV001V: RhoVac
27. ProstAtak: Advantagene
And many others

Table of contents
1. Key Insights
2. Executive Summary of Prostate Cancer
3. SWOT Analysis of Prostate Cancer
4. Prostate Cancer Market Overview at a Glance
5. Prostate Cancer Disease Background and Overview
6. Prostate Cancer Diagnosis
7. Prostate Cancer Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.4. The United States Epidemiology
8. EU-5 Country-wise Prostate Cancer Epidemiology
8.1. Germany
8.2. France
8.3. Italy
8.4. Spain
8.5. United Kingdom
8.6. Japan
9. Prostate Cancer Current Treatment Practices
10. Guideline of Prostate Cancer
11. Unmet Needs of Prostate Cancer
12. Prostate Cancer Marketed Therapies
12.1. Key Cross
12.2. Xofigo (radium Ra 223 dichloride): Bayer Health Care
12.3. Xtandi (Enzalutamide): Astellas Pharma
12.4. Prolia (denosumab): Amgen
12.5. Erleada (apalutamide): Janssen Pharmaceutical
12.6. Jevtana (Cabazitaxel): Sanofi
12.7. Nubeqa (Darolutamide/ODM-201): Bayer HealthCare/Orion Corporation
13. Prostate Cancer Emerging Therapies
13.1. Lynparza (Olaparib): AstraZeneca/ Merck Sharp & Dohme
13.2. Opdivo (nivolumab): Bristol-Myers Squibb
13.3. 177Lu-PSMA-617: Novartis
13.4. Relugolix: Myovant Sciences/Takeda
13.5. HC-1119: Hinova Pharmaceuticals
13.6. Seviteronel (VT-464): Innocrin Pharmaceutical
13.7. PROSTVAC-V/F: Bavarian Nordic
13.8. ODM-208: Orion Pharma
13.9. Sacituzumab Govitecan (IMMU-132): Immunomedics
13.10. Keytruda (Pembrolizumab/MK-3475): Merck Sharp & Dohme
13.11. Ipatasertib (RG7440): Hoffmann-La Roche
13.12. Talazoparib: Pfizer/Astellas Pharma
13.13. Capivasertib (AZD5363): AstraZeneca
13.14. AZD4635: AstraZeneca
13.15. PRX302 (topsalysin): Sophiris Bio
13.16. Pamiparib (BGB-290): BeiGene
13.17. Enoblituzumab (MGA271): MacroGenics
13.18. Tisotumab Vedotin: Genmab
13.19. Dupilumab: Regeneron Pharmaceuticals
13.20. Rubraca (Rucaparib): Clovis Oncology
13.21. Niraparib: Janssen Research & Development
13.22. Proxalutamide (GT0918): Suzhou Kintor Pharmaceutical
13.23. Abemaciclib (LY2835219): Eli Lilly and Company
13.24. Tomivosertib (eFT508): eFFECTOR Therapeutics
13.25. Onvansertib: Trovagene
13.26. RV001V: RhoVac
13.27. ProstAtak: Advantagene
14. Prostate Cancer Seven Major Market Analysis
15. Prostate Cancer 7MM Market Size
15.1. Total Market Size of Prostate Cancer in the 7MM
15.2. Total Market size of CSPC by Therapies in the 7MM
15.3. Total Market size of CRPC by Therapies in the 7MM
15.4. United States Market Size
15.5. EU-5 Market Size
15.5.1. Germany Market Size
15.5.2. France Market Size
15.5.3. Italy Market Size
15.5.4. Spain Market Size
15.5.5. United Kingdom Market Size
15.6. Japan Market Size
16. Market Access and Reimbursement of Prostate Cancer
17. Market Drivers of Prostate Cancer
18. Market Barriers of Prostate Cancer
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:

info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 05/28/2020 -- Hepatocellular Carcinoma Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Hepatocellular Carcinoma Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total Hepatocellular Carcinoma incident population in the G8 was 460,992 in 2017.
2. Japan had 38,261 HCC incident cases in 2017.
3. Males account for the highest number of incident patients with Hepatocellular Carcinoma.

Key benefits of the report
1. Hepatocellular Carcinoma market report covers a descriptive overview and comprehensive insight of the HCC epidemiology and Hepatocellular Carcinoma market in the United States, EU5 (Germany, Spain, France, Italy, UK), Japan and China.
2. HCC market report provides insights into the current and emerging therapies.
3. Hepatocellular Carcinoma market report provides a global historical and forecasted market covering drug outreach.
4. HCC market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hepatocellular Carcinoma market.

Request for sample pages

"Hepatocellular Carcinoma Market Size in the G8 was 709.19 Million in 2017".

Hepatocellular Carcinoma is a dreadful condition. Currently, there are few approved drugs for unresectable hepatocellular carcinoma, but researchers are actively engaged in finding the cure by targeting other pathways. One hope is that by using combinational therapies, a person with HCC will be able to live a better life.

Generally, Hepatocellular Carcinoma treatment patients is recommended at early-stage HCC and may not be recommended for the patients with later stages of the disease. Currently, the major treatment options of Hepatocellular Carcinoma are:

Hepatic Resection is the treatment for hepatocellular carcinoma in patients without cirrhosis, in whom major resections could be done without life-threatening complications. In patients with decompensated cirrhosis, hepatic Resection is formally contraindicated, and liver transplantation should be considered. Patients with compensated cirrhosis should be carefully evaluated to avoid treatment-related complications and achieve long-term survival.

Theoretically, liver transplantation is the best treatment option since it might simultaneously cure the tumour and the underlying cirrhosis. The likelihood of patient survival after transplantation remains the essential criterion to indicate Hepatocellular Carcinoma treatment. Other than this, Image-guided transcatheter tumour therapies aim to induce tumour necrosis and are based on the predominantly arterial vascularization of hepatocellular carcinoma compared with the surrounding liver parenchyma.

Recent developments in drug portfolio have impacted the overall HCC treatment regimen. Sorafenib and Miripla (Japan) were the first approved therapy and had a 10-year long hold on the market. Now, Lenvatinib has also been approved as first-line therapy. Furthermore, Opdivo, Regorefinib, Keytruda, Cyramza, and Carbometyx have opted as second-line therapies along with some off-label Hepatocellular Carcinoma treatment option.

The launch of the emerging therapies is expected to significantly impact Hepatocellular Carcinoma treatment scenario in the upcoming years:-
Drugs covered
1. ATG-008
2. SHR-1210
And many others

The key players in Hepatocellular Carcinoma market are:
1. Antengene Therapeutics
2. Jiangsu HengRui Medicine
And many others

Table of contents
1. Key Insights
2. Hepatocellular Carcinoma Market Overview at a Glance
3. HCC Disease Background and Overview
4. Hepatocellular Carcinoma Epidemiology and Patient Population
5. Key Findings
6. HCC Population and Forecast Parameters
7. Country Wise-HCC Epidemiology
7.1. United States
7.2. EU5 Countries
7.3. Germany
7.4. France
7.5. Italy
7.6. Spain
7.7. United Kingdom
7.8. Japan
7.9. China
8. Treatment Practices
9. Unmet Needs
10. Hepatocellular Carcinoma Marketed Drug Analysis
10.1. Nexavar: Bayer HealthCare
10.2. Miripla: Sumitomo Dainippon Pharma
10.3. Opdivo: Bristol-Myers Squibb
11. Hepatocellular Carcinoma Emerging Therapies
12. HCC Emerging Drugs Analysis
12.1. ATG-008: Antengene Therapeutics
12.2. SHR-1210: Jiangsu HengRui Medicine
13. Failure in Phase III Clinical trials for Hepatocellular Carcinoma
14. Hepatocellular Carcinoma G8 Countries Market Analysis
15. Key Findings
15.1. Total Market Size of Hepatocellular Carcinoma in G8 Countries
15.2. G8 Countries Market Size of HCC by Line of Therapies
15.3. G8 Countries Market Size of HCC by Therapies
16. Hepatocellular Carcinoma Market Outlook by Country
16.1. The United States: Market Outlook
16.2. EU-5 Countries: Market Outlook
16.3. Germany
16.4. France
16.5. Italy
16.6. Spain
16.7. United Kingdom
16.8. Japan: Market Outlook
16.9. China: Market Outlook
17. Market Drivers
18. Market Barriers
19. Appendix
20. Hepatocellular Carcinoma Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 05/27/2020 -- Immune Thrombocytopenia Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Immune Thrombocytopenia Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total ITP prevalent population in 7MM was approximately 180,498 in 2017.
2. The total diagnosed prevalent cases in the 7MM were estimated to be approximately 147,174 in 2017.
3. The majority of ITP cases are females as compared to males.

Key benefits of the report
1. Immune Thrombocytopenia market report covers a descriptive overview and comprehensive insight of the Immune Thrombocytopenia epidemiology and Immune Thrombocytopenia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Immune Thrombocytopenia market report provides insights into the current and emerging therapies.
3. Immune Thrombocytopenia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Immune Thrombocytopenia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Immune Thrombocytopenia market.

Request for sample pages

"Immune Thrombocytopenia market size was USD 2,527.72 million in the 7 MM in 2017".

The United States reports having the highest ITP market size, in comparison to the other major markets, i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Among the EU5 countries, the UK had the highest Immune Thrombocytopenia market size, with approximately USD 247.89 million in 2017, while Spain had the smallest ITP market size of ITP, with approximately USD 115.08 million in 2017.

With the anticipated launch of upcoming therapies such as BT595 (Biotest) in 2021; UCB7665 (UCB Biopharma) in and ARGX-113 (Argenx BVBA) in 2023, the market will experience significant growth. The FDA has approved three TPO-RA therapies: romiplostim (Nplate), eltrombopag (Promacta), and avatrombopag (Doptelet). For Europe and Japan, only two TPO-RAs is approved, i.e., Nplate and Promacta. Promacta and Nplate will lose their patent in 2022 in the US, whereas in Europe, Nplate losses the patent in 2019 and Promacta will lose patent in 2025. Due to their patent expiry, it is expected that the approval of Doptelet is likely to cover a significant patient pool.

The launch of the emerging therapies is expected to significantly impact Immune Thrombocytopenia treatment scenario in the upcoming years:-
Drugs covered
1. BT-595
2. GC5107A
3. LIV-Gamma SN Inj.
4. Hetrombopag Olamine
5. Efgartigimod (ARGX-113)
6. SKI-O-703
7. KZR-616
8. Rozanolixizumab
9. BMS-986004 (Letolizumab)
10. PRN-1008
11. PRTX-100
And many others
The key players in Immune Thrombocytopenia market are:
1. Biotest
2. GC Pharma
3. SK Plasma
4. Jiangsu HengRui Medicine
5. Argenx
6. Genosco
7. Kezar Life Sciences
8. UCB Biopharma
9. Bristol-Myers Squibb
10. Principia Biopharma
11. Protalex
And many others

Table of contents
1. Key Insights
2. Executive Summary of Immune Thrombocytopenia
3. SWOT Analysis for Immune Thrombocytopenia
4. Immune Thrombocytopenia Market Overview at a Glance
5. Immune Thrombocytopenia Disease Background and Overview
6. Immune Thrombocytopenia Epidemiology and Patient Population
7. Country Wise-Epidemiology of Immune Thrombocytopenia (ITP)
7.1. United States Epidemiology
7.2. EU5 Epidemiology
7.2.1. Germany
7.2.2. France
7.2.3. Italy
7.2.4. Spain
7.2.5. United Kingdom
7.3. Japan Epidemiology
8. Immune Thrombocytopenia Treatment and Management
9. Patient Journey of Immune Thrombocytopenia
10. Unmet Needs
11. Key Endpoints of Immune Thrombocytopenia
12. Immune Thrombocytopenia Marketed Drugs
12.1. Key Cross Competition
12.2.Octagam: Octapharma USA
12.4. Privigen: CSL Behring
12.5. Rhophylac: CSL Behring
12.6. Doptelet (Avatrombopag): Dova Pharmaceuticals
12.7. Tavalisse (fostamatinib disodium hexahydrate): Rigel Pharmaceuticals
12.8. Rituximab: Zenyaku Kogyo/Biogen Idec
12.9. Promacta (eltrombopag): Novartis
12.10. Gammaplex: Bio Products Laboratory's
12.11. Takecab: Takeda Pharmaceutical Company Limited
12.12. Nexium Capsules: AstraZeneca
13. Immune Thrombocytopenia Emerging Drugs
13.1. Key Cross Competition
13.2. BT-595: Biotest
13.3. GC5107A: GC Pharma
13.4. LIV-Gamma SN Inj.: SK Plasma
13.5. Hetrombopag Olamine: Jiangsu HengRui Medicine
13.6. Efgartigimod (ARGX-113): Argenx
13.7. SKI-O-703: Genosco (a US-based subsidiary of Korean bio company Oscotec)
13.8. KZR-616: Kezar Life Sciences
13.9. Rozanolixizumab: UCB Biopharma
13.10. BMS-986004 (Letolizumab): Bristol-Myers Squibb
13.11. PRN-1008: Principia Biopharma
13.12. PRTX-100: Protalex
14. Attribute Analysis of Immune Thrombocytopenia Therapies
15. Immune Thrombocytopenia Seven Major Market Analysis
16. Market Outlook: The United States
16.1. United States Market Size
17. Market Outlook: Europe
17.1. Germany
17.2. France
17.3. Italy
17.4. Spain
18. Market Outlook: Japan
19. Access and Reimbursement Overview for Current and Future Therapies
20. Market Drivers
21. Market Barriers
22. Appendix
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 05/26/2020 -- Prurigo Nodularis Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Prurigo Nodularis Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total diagnosed Prurigo Nodularis prevalent population in the 7MM was found to be 539,893 in 2017.
2. The total diagnosed prevalent patient population of Prurigo Nodularis in the 7MM was around 46.30% of the total cases in the United States in 2017.
3. Females are affected more by Prurigo Nodularis as compared to males.

Key benefits of the report
1. Prurigo Nodularis market report covers a descriptive overview and comprehensive insight of the Prurigo Nodularis epidemiology and Prurigo Nodularis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Prurigo Nodularis market report provides insights into the current and emerging therapies.
3. Prurigo Nodularis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Prurigo Nodularis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Prurigo Nodularis market.

Request for sample pages

"Prurigo Nodularis market was USD 344.89 Million in the United States in 2017."

Prurigo Nodularis treatment is challenging. The current Prurigo Nodularis market can be classified based on the severity of the disease as mild, moderate, and severe. There is a multimodal treatment algorithm consisting of topical and systemic therapies, where topical therapies are used for treating the visible form of the disease. In contrast, systemic therapies are used for symptomatic treatment. The symptomatic therapy aims to reduce itching and complete healing of lesions. A mild form of the disease includes several topical therapies, such as antihistamines, topical corticosteroids, topical immunosuppressants, topical calcineurin inhibitors, emollients, which are recommended as both an essential therapy and general therapeutic measure.

Topical corticosteroid includes Betamethasone 0.1% cream, which reduces itch significantly, in comparison with an antipruritic moisturizing cream, and also results in nodule flattening. Topical calcineurin inhibitors or immunosuppressants represent a relatively long-term treatment option.

On the other hand, for moderate-to-severe forms of the disease, topical corticosteroids (Betamethasone 0.1%), topical Immunosuppressants/Topical calcineurin inhibitors (pimecrolimus and Tacrolimus), systemic immunosuppressants (for moderate-to-severe cases), systemic corticosteroid (triamcinolone acetonide) along with other relevant therapies such as antidepressants (paroxetine, amitriptyline or mirtazapine), gabapentinoids and opioid receptor antagonists are suggested usually.

Immunosuppressants are considered as a therapeutic option for patients with moderate-to-severe Prurigo Nodularis mainly. Several studies have described the application of immunosuppressive agents, such as cyclosporine in the disease, showing remarkable symptom improvement. During immunosuppressant therapy, it is essential to monitor blood pressure and laboratory values, especially those of the kidneys. Thalidomide and its analogue Lenalidomide are other immunomodulatory drugs that have successfully been used to treat refractory cases of Prurigo Nodularis.

The launch of the emerging therapies is expected to significantly impact Prurigo Nodularis treatment scenario in the upcoming years:-

Drugs covered
1. Serlopitant
2. Nalbuphine ER
3. Nemolizumab (CD14152)
4. Apremilast (CC-10004)
5. M 118103
6. KPL-716
7. Dupixent (Dupilumab/SAR231893)
And many others

The key players in Prurigo Nodularis market are:
1. Menlo Therapeutics
2. Trevi Therapeutics
3. Galderma
4. Amgen
5. Maruho
6. Kiniksa Pharmaceuticals
7. Sanofi
8. Regeneron Pharmaceuticals
And many others

Table of contents
1 Key Insights
2 Prurigo Nodularis Patient Overview at a Glance
3 Executive Summary
4 SWOT Analysis
5 Disease Background and Overview of Prurigo Nodularis
6 Recognized Establishments
7 Prurigo Nodularis Epidemiology and Patient Population
8 Country-wise Epidemiology of Prurigo nodularis
8.1 United States
8.2 EU5 Countries
8.3 Germany
8.4 France
8.5 Italy
8.6 Spain
8.7 United Kingdom
8.8 Japan
9 Prurigo Nodularis Treatment
10 European Guidelines on Prurigo Nodularis
11 FDA Recommendations for Prurigo Nodularis Treatment
12 Unmet Need
13 Prurigo Nodularis Emerging Drugs
13.1 Key Competitors
13.2 Serlopitant: Menlo Therapeutics
13.3 Nalbuphine ER: Trevi Therapeutics
13.4 Nemolizumab (CD14152): Galderma
13.5 Apremilast (CC-10004): Amgen
13.6 M 118103: Maruho
13.7 KPL-716: Kiniksa Pharmaceuticals
13.8 Dupixent (Dupilumab/SAR231893): Sanofi/Regeneron Pharmaceuticals
14 Prurigo Nodularis Market Size
15 Attribute Analysis
16 Conjoint Analysis
17 7MM Prurigo Nodularis Market Outlook
17.1 United States
18 EU5 Countries
18.1 Germany
18.2 France
18.3 Italy
18.4 Spain
18.5 United Kingdom
19 Japan
20 Case Reports
21 Market Drivers
22 Market Barriers
23 Appendix
24 Prurigo Nodularis Report Methodology
25 DelveInsight Capabilities
26 Disclaimer
27 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm